<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nature.com/articles/s41386-023-01588-2">Original</a>
    <h1>Dose-response relationships of LSD-induced subjective experiences in humans</h1>
    
    <div id="readability-page-1" class="page"><div data-test="context-bar" data-context-bar="" aria-hidden="true">
                <div>
                    <p>
                        Dose-response relationships of LSD-induced subjective experiences in humans
                    </p>
                    
    
        
    

                </div>
                
            </div><article lang="en">
            
                
            
            

        <div>
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div id="Abs1-section"><h2 id="Abs1">Abstract</h2><p>Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness. Here we present the first meta-analysis establishing dose-response relationship estimates of the altered states of consciousness induced by LSD. Data extracted from articles identified by a systematic literature review following PRISMA guidelines were obtained from the Altered States Database. The psychometric data comprised ratings of subjective effects from standardized and validated questionnaires: the Altered States of Consciousness Rating Scale (5D-ASC, 11-ASC) and the Mystical Experience Questionnaire (MEQ30). We performed meta-regression analyses using restricted cubic splines for data from studies with LSD doses of up to 200 μg base. Most scales revealed a sigmoid-like increase of effects, with a plateauing at around 100 μg. The most strongly modulated factors referred to changes in perception and illusory imagination, followed by positively experienced ego-dissolution, while only small effects were found for Anxiety and Dread of Ego Dissolution. The considerable variability observed in most factors and scales points to the role of non-pharmacological factors in shaping subjective experiences. The established dose-response relationships may be used as general references for future experimental and clinical research on LSD to compare observed with expected subjective effects and to elucidate phenomenological differences between psychedelics.</p></div></section>
            

                
            
                <div>
                <section data-title="Introduction"><div id="Sec1-section"><h2 id="Sec1">Introduction</h2><div id="Sec1-content"><p>Lysergic acid diethylamide (LSD) is the prototype of classic serotonergic psychedelics, a group of substances which unfold their psychoactive properties predominantly via the serotonin 2 A (5-HT<sub>2A</sub>) receptor [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897–902. 
                https://doi.org/10.1097/00001756-199812010-00024
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR1" id="ref-link-section-d413946755e372">1</a>]. Psychedelics embrace structurally heterogenous subgroups like phenethylamines (e.g., mescaline) and tryptamines (e.g., psilocybin, <i>N,N</i>-DMT) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Nichols DE. Chemistry and Structure–Activity Relationships of Psychedelics. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behav. Neurobiol. Psychedelic Drugs, vol. 36, Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. p. 1–43. 
                https://doi.org/10.1007/7854_2017_475
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR2" id="ref-link-section-d413946755e378">2</a>], as well as substances from the ergoline subgroup (e.g., LSD) which have been characterized as “rigidified tryptamines” [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Nichols DE. Psychedelics. Pharm Rev. 2016;68:264–355. 
                https://doi.org/10.1124/pr.115.011478
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR3" id="ref-link-section-d413946755e381">3</a>]. The term ‘psychedelics’ is also used in a broader sense, including non-serotonergic drugs like ketamine, PCP or MDMA. The use of the term ‘psychedelic experience’ is not limited to the effects induced by specific substances, instead refers to a group of psychological effects. However, there is no clear definition on the exact set of consciousness alterations that define a psychedelic experience. Here, we will refer to classic serotonergic psychedelics and the effects they induce when using the term ‘psychedelics’ or ‘psychedelic experience’. Several studies suggest that qualitatively, LSD might not be differentiated from other psychedelics with regard to the induced psychologic effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hartman AM, Hollister LE. Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia. 1963;4:441–51. 
                https://doi.org/10.1007/BF00403349
                
              ." href="#ref-CR4" id="ref-link-section-d413946755e385">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7. 
                https://doi.org/10.1038/s41386-022-01297-2
                
              ." href="#ref-CR5" id="ref-link-section-d413946755e385_1">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962;3:219–23. 
                https://doi.org/10.1007/BF00412109
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR6" id="ref-link-section-d413946755e388">6</a>]. On the other hand, anecdotal reports mention differences in subjective experiences regarding different substances [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Shulgin AT, Shulgin A. Tihkal: the continuation. Berkeley:Transform; 1997." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR7" id="ref-link-section-d413946755e391">7</a>], and LSD somewhat differs from pharmacodynamical profiles of other 5-HT<sub>2A</sub> agonists, including a broader variety of receptor targets [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Nichols DE. Psychedelics. Pharm Rev. 2016;68:264–355. 
                https://doi.org/10.1124/pr.115.011478
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR3" id="ref-link-section-d413946755e396">3</a>].</p><p>After its initial synthesis in 1938, LSD’s psychedelic properties have accidentally been discovered in 1943 by the Swiss pharmacologist Albert Hofmann [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Hofmann A. LSD, my problem child and insights/outlooks. Beckley Foundation. Oxford University Press; 2013." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR8" id="ref-link-section-d413946755e402">8</a>]. Ever since, LSD has been the most extensively investigated psychedelic from the 1950s to the 1970s, with more than 1000 scientific papers published in the context of basic science, as well as in clinical research as a therapeutic tool [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol (Oxf). 2015;29:241–53. 
                https://doi.org/10.1177/0269881114568040
                
              ." href="#ref-CR9" id="ref-link-section-d413946755e405">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642–51. 
                https://doi.org/10.1038/nrn2884
                
              ." href="#ref-CR10" id="ref-link-section-d413946755e405_1">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24. 
                https://doi.org/10.1038/s41583-020-0367-2
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR11" id="ref-link-section-d413946755e408">11</a>]. Most intensively studied indications included, among others, alcoholism [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (Oxf). 2012;26:994–1002. 
                https://doi.org/10.1177/0269881112439253
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR12" id="ref-link-section-d413946755e411">12</a>] and existential distress in life-threatening physical illness [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:1–10. 
                https://doi.org/10.1016/j.pnpbp.2017.09.012
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR13" id="ref-link-section-d413946755e414">13</a>]. After a hiatus of more than 20 years, during which regulatory hurdles prevented research on psychedelics, research eventually resumed in the 1990s. Also, in recreational underground use LSD is by far the most frequently used psychedelic worldwide [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Evens R, Reiche S, Marek RM, Moon DU, Groß RE, Romanello A, et al. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey. Front Psychiatry. 2021;12:732028 
                https://doi.org/10.3389/fpsyt.2021.732028
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR14" id="ref-link-section-d413946755e418">14</a>], and doses of psychedelics are often compared to LSD equivalents by users.</p><p>LSD has recently been re-evaluated for the treatment of different mental health conditions, like anxiety and depression in patients with [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2022:S0006322322015530. 
                https://doi.org/10.1016/j.biopsych.2022.08.025
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR15" id="ref-link-section-d413946755e424">15</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. J Nerv Ment Dis. 2014;202:513–20. 
                https://doi.org/10.1097/NMD.0000000000000113
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR16" id="ref-link-section-d413946755e427">16</a>] and without life-threatening illness [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2022:S0006322322015530. 
                https://doi.org/10.1016/j.biopsych.2022.08.025
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR15" id="ref-link-section-d413946755e430">15</a>]. Psychological effects of psychedelics underlie specific temporal dynamics [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol (Oxf). 2015;29:241–53. 
                https://doi.org/10.1177/0269881114568040
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR9" id="ref-link-section-d413946755e433">9</a>], including (acute) psychedelic experiences, subacute effects, and long-term (enduring) effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol Oxf Engl. 2011;25:1434–52. 
                https://doi.org/10.1177/0269881110382466
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR17" id="ref-link-section-d413946755e436">17</a>]. There is some evidence that the quality and intensity of acute psychedelic effects might predict therapeutic outcome [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharm Transl Sci. 2021;4:568–72. 
                https://doi.org/10.1021/acsptsci.0c00194
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR18" id="ref-link-section-d413946755e440">18</a>]. Thus, the classification and description of acute psychedelic experiences appear to be of high importance when it comes to optimizing treatment interventions regarding efficacy and safety. In order to determine the optimal dosing ranges of LSD for future clinical studies, first and most importantly the influence of the LSD dose on the nature and intensity of acute subjective effects needs characterization. Over the last decades some gold standards for the assessment of altered states phenomena have been established in terms of several well-validated questionnaires for a retrospective assessment of altered experiences [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol (Oxf). 2015;29:241–53. 
                https://doi.org/10.1177/0269881114568040
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR9" id="ref-link-section-d413946755e443">9</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schmidt TT, Majić T. Empirische Untersuchung veränderter Bewusstseinszustände. Handb. Psychoaktive Subst., Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. 
                https://doi.org/10.1007/978-3-642-55214-4_65-1
                
              ." href="#ref-CR19" id="ref-link-section-d413946755e446">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hirschfeld T, Schmidt TT. Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol (Oxf). 2021;35:384–97. 
                https://doi.org/10.1177/0269881121992676
                
              ." href="#ref-CR20" id="ref-link-section-d413946755e446_1">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D. Systematic Review of Psychometric Instruments Used in Research with Psychedelics. J Psychoactive Drugs. 2022 May 26:1–10. 
                https://doi.org/10.1080/02791072.2022.2079108
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR21" id="ref-link-section-d413946755e449">21</a>]. Such standardized assessment allows meta-analytic comparisons, as recently presented to establish dose-response relationships for altered experiences induced by psilocybin [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Hirschfeld T, Schmidt TT. Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol (Oxf). 2021;35:384–97. 
                https://doi.org/10.1177/0269881121992676
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR20" id="ref-link-section-d413946755e452">20</a>].</p><p>The data to establish dose-response relationships for LSD is limited by the availability of studies that cohere to current research standards, as LSD has only recently returned to basic and clinical research. The range of LSD doses employed in current research is on average markedly below the doses administered in studies from the 1950 to 70 s. At that time, high doses mostly ranging between 400 and 600 μg were applied, especially in the treatment of alcohol use disorder, whereas in recent studies doses of 200 μg have not been exceeded, neither in healthy subjects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e458">22</a>], nor in clinical samples [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2022:S0006322322015530. 
                https://doi.org/10.1016/j.biopsych.2022.08.025
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR15" id="ref-link-section-d413946755e461">15</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. J Nerv Ment Dis. 2014;202:513–20. 
                https://doi.org/10.1097/NMD.0000000000000113
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR16" id="ref-link-section-d413946755e464">16</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol Oxf Engl. 2015;29:57–68. 
                https://doi.org/10.1177/0269881114555249
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR23" id="ref-link-section-d413946755e467">23</a>]. Regarding the lower end of the dose spectrum, applications of so-called microdosing are gaining increasing interest both in recreational and scientific settings. It is thought that such low doses, which do not induce subjectively identifiable drug effects, can positively affect cognitive processes and improve mental health indicators [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706 
                https://doi.org/10.1016/j.neubiorev.2022.104706
                
              ." href="#ref-CR24" id="ref-link-section-d413946755e470">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol Oxf Engl. 2016;30:1181–97. 
                https://doi.org/10.1177/0269881116675513
                
              ." href="#ref-CR25" id="ref-link-section-d413946755e470_1">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;41:81–91. 
                https://doi.org/10.1016/j.euroneuro.2020.10.002
                
              ." href="#ref-CR26" id="ref-link-section-d413946755e470_2">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Hutten NRPW, Mason NL, Dolder PC, et al. KPC. Motives and Side-Effects of Microdosing With Psychedelics Among Users. Int J Neuropsychopharmacol. 2019;22:426–34. 
                https://doi.org/10.1093/ijnp/pyz029
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR27" id="ref-link-section-d413946755e474">27</a>]. The exact dose range of LSD microdosing is still debated; a recent literature review suggests a “plausible microdose range” for LSD of 6–20 μg [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706 
                https://doi.org/10.1016/j.neubiorev.2022.104706
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR24" id="ref-link-section-d413946755e477">24</a>]. Only few studies directly tested the dose-dependency of LSD’s effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e480">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;41:81–91. 
                https://doi.org/10.1016/j.euroneuro.2020.10.002
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR26" id="ref-link-section-d413946755e483">26</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e486">28</a>]. With the application of within-subject designs, these studies provide well-controlled experimental conditions, while they do not allow to assess study-specific impacts on participants experiences. Such non-pharmacological effects appear, however, particularly pronounced for psychedelic substances, and are generally referred to as <i>set and setting</i> effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, et al. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. J Affect Disord. 2023;326:18–25. 
                https://doi.org/10.1016/j.jad.2023.01.077
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR29" id="ref-link-section-d413946755e493">29</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Zinberg NE. Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. New Haven CT, Yale University Press; 1984." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR30" id="ref-link-section-d413946755e496">30</a>]. Cross-study comparisons are essential to obtain data-based estimates of the variability of subjective LSD experiences across research sites and experimental protocols, as no corresponding meta-analysis is available to date.</p><p>With the present meta-analysis, we aim to obtain estimates of the relationship between LSD doses and the quality of psychedelic experiences. The data stem from the Altered States Database (ASDB, <a href="http://alteredstatesdb.org">http://alteredstatesdb.org</a>, [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Schmidt TT, Berkemeyer H. The Altered States Database: Psychometric Data of Altered States of Consciousness. Front Psychol. 2018;9:720 
                https://doi.org/10.3389/fpsyg.2018.01028
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR31" id="ref-link-section-d413946755e510">31</a>]), which is a regularly updated database with questionnaire data extracted from articles identified by a systematic literature review, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Statement Guidelines [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. 
                https://doi.org/10.1136/bmj.n71
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR32" id="ref-link-section-d413946755e513">32</a>]. Available data was found for the Altered States of Consciousness Rating Scale (5D-ASC, 11-ASC) and the Mystical Experience Questionnaire (MEQ30) for a dose range up to 200 μg.</p></div></div></section><section data-title="Methods"><div id="Sec2-section"><h2 id="Sec2">Methods</h2><div id="Sec2-content"><h3 id="Sec3">Included data</h3><p>Psychometric questionnaire data on the subjective experience of LSD were included in this meta-analysis. The data has been retrieved from the ASDB repository on Open Science Framework (OSF; <a href="https://osf.io/8mbru">https://osf.io/8mbru</a>, version ASDB_v.2022-12-31), which contains data from MEDLINE-listed studies on altered states of consciousness published from 1975-01-01 to 2022-12-31. The ASDB stems from a systematic literature review according to PRISMA standards [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. 
                https://doi.org/10.1136/bmj.n71
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR32" id="ref-link-section-d413946755e535">32</a>] as described in Prugger et al. (2022) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT. The Altered States Database: Psychometric data from a systematic literature review. Sci Data. 2022;9:720 
                https://doi.org/10.1038/s41597-022-01822-4
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR33" id="ref-link-section-d413946755e538">33</a>] and Peters et al. (2023) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Peters M, Prugger J, Dimkov P, Schmidt TT. Update of the Altered States Database (ASDB): 2022-12-31. 
                https://doi.org/10.31234/osf.io/wdfhg.
                
               Accessed 02 May 2023." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR34" id="ref-link-section-d413946755e541">34</a>]. Datasets investigating the subjective effects of LSD were retrieved from the ASDB. The PRISMA flowchart showing the process of item identification and screening can be found in the Supplementary Material.</p><p>Data were excluded if experimental conditions comprised applications of combinations of substances [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e547">28</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol CB. 2017;27:451–7. 
                https://doi.org/10.1016/j.cub.2016.12.030
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR35" id="ref-link-section-d413946755e550">35</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Front Pharm. 2017;8:814 
                https://doi.org/10.3389/fphar.2017.00814
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR36" id="ref-link-section-d413946755e553">36</a>] such as pre-treatments with ketanserin, if the LSD dose was unclear [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Schmid Y, Gasser P, Oehen P, Liechti ME. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol Oxf Engl. 2021;35:362–74. 
                https://doi.org/10.1177/0269881120959604
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR37" id="ref-link-section-d413946755e556">37</a>], or if data were about recreational LSD usage [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R. Survey of subjective ‘God encounter experiences’: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PloS ONE. 2019;14:e0214377 
                https://doi.org/10.1371/journal.pone.0214377
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR38" id="ref-link-section-d413946755e559">38</a>]. From studies reporting multiple questionnaire applications at different time points during the same day of the experimental session [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e563">39</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stampfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082 
                https://doi.org/10.7554/eLife.35082
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR40" id="ref-link-section-d413946755e566">40</a>], only the final and complete questionnaire application was included describing the overall experience. Also, after consultation with the authors, the LSD doses in a series of reports [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e569">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol CB. 2017;27:451–7. 
                https://doi.org/10.1016/j.cub.2016.12.030
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR35" id="ref-link-section-d413946755e572">35</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Front Pharm. 2017;8:814 
                https://doi.org/10.3389/fphar.2017.00814
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR36" id="ref-link-section-d413946755e575">36</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e578">39</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Müller F, Lenz C, Dolder P, Lang U, Schmidt A, Liechti M, et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand. 2017;136:648–57. 
                https://doi.org/10.1111/acps.12818
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR41" id="ref-link-section-d413946755e582">41</a>] were adjusted as suggested in [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e585">28</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Holze F, Duthaler U, Vizeli P, Müller F, Borgwardt S, Liechti ME. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharm. 2019;85:1474–83. 
                https://doi.org/10.1111/bcp.13918
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR42" id="ref-link-section-d413946755e588">42</a>], due to administration of capsules containing an unstable LSD formulation leading to dispersion of lower than presumed LSD doses. Studies reporting on administration of both LSD base and LSD tartrate have been included. LSD tartrate doses (from studies [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacol (Berl). 2021. 
                https://doi.org/10.1007/s00213-021-05991-9
                
              ." href="#ref-CR43" id="ref-link-section-d413946755e591">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019;86:792–800. 
                https://doi.org/10.1016/j.biopsych.2019.05.019
                
              ." href="#ref-CR44" id="ref-link-section-d413946755e591_1">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143 
                https://doi.org/10.1111/adb.13143
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR45" id="ref-link-section-d413946755e594">45</a>]) were converted to the LSD base equivalent by multiplying by 0.685 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Holze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clin Pharm Ther. 2021;109:658–66. 
                https://doi.org/10.1002/cpt.2057
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR46" id="ref-link-section-d413946755e597">46</a>] (See Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://www.nature.com/articles/s41386-023-01588-2#Tab1">1</a>).</p><div data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption><b id="Tab1" data-test="table-caption">Table 1 Summary of studies included in the meta-regression analyses.</b></figcaption></figure></div><h3 id="Sec4">Questionnaires</h3><p>This meta-analysis included psychometric data from commonly applied questionnaires to assess the phenomenology of altered states of consciousness, namely from two versions of the Altered States of Consciousness Rating Scale (the 5D-ASC and the 11-ASC), and from the Mystical Experience Questionnaire (MEQ30). The Altered States of Consciousness Rating Scale [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Dittrich A. Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände [Construction of a questionnaire (APZ) for assessing abnormal mental states]. Z Klin Psychol Psychiatr Psychother. 1975;23:12–20." href="#ref-CR47" id="ref-link-section-d413946755e1589">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Dittrich A. Ätiologie-unabhängige Strukturen veränderter Wachbewußtseinszustände: Ergebnisse empirischer Untersuchungen über Halluzinogene I. und II. Ordnung, sensorische Deprivation, hypnagoge Zustände, hypnotische Verfahren sowie Reizüberflutung. [Etiology-independent structures of altered states of consciousness. Results of empirical studies on hallucinogens of the first and second order, sensory deprivation, hypnagogic states, hypnotic procedures, and sensory overload]. Enke, Stuttgart, Germany; 1985." href="#ref-CR48" id="ref-link-section-d413946755e1589_1">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80–4. 
                https://doi.org/10.1055/s-2007-979351
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR49" id="ref-link-section-d413946755e1592">49</a>] is a self-report questionnaire with 94 items rated on a visual analog scale. Two different analysis schemata are in use: In the 5D-ASC version (“5-Dimensional Altered States of Consciousness Rating Scale” [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Bodmer I, Dittrich A, Lamparter D. Aussergewöhnliche Bewusstseinszustände-Ihre gemeinsame Struktur und Messung [Altered states of consciousness-Their common structure and assessment]. Welten Bewusstseins Bd. 1994;3:45–58." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR50" id="ref-link-section-d413946755e1595">50</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Dittrich A, Lamparter D, Maurer M. 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]. PSIN PLUS, Zurich, Switzerland; 2006." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR51" id="ref-link-section-d413946755e1598">51</a>]), items are assigned to five core dimensions: (1) <i>Auditory Alterations</i>, (2) <i>Dread of Ego Dissolution</i>, (3) <i>Oceanic Boundlessness</i>, (4) <i>Visionary Restructuralization</i>, and (5) <i>Vigilance Reduction</i>. In the more recent 11-ASC version (“11-factor Altered States of Consciousness Rating Scale” [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Studerus E, Gamma A, Vollenweider FX. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE. 2010;5:e12412 
                https://doi.org/10.1371/journal.pone.0012412
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR52" id="ref-link-section-d413946755e1617">52</a>]), only 42 of the 94 questionnaires items are used in the analysis, in which item scores are summarized along 11 factors: (1) <i>Experience of Unity</i>, (2) <i>Spiritual Experience</i>, (3) <i>Blissful State</i>, (4) <i>Insightfulness</i>, (5) <i>Disembodiment</i>, (6) <i>Impaired Control and Cognition</i>, (7) <i>Anxiety</i>, (8) <i>Complex Imagery</i>, (9) <i>Elementary Imagery</i>, (10) <i>Audio-Visual Synesthesia</i>, and (11) <i>Changed Meaning of Percepts</i>. Both analysis schemes have been validated and demonstrate good reliability (5D-ASC: Hoyt 0.88–0.95 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Dittrich A, Lamparter D, Maurer M. 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]. PSIN PLUS, Zurich, Switzerland; 2006." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR51" id="ref-link-section-d413946755e1655">51</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Dittrich A, Lamparter D, Maurer M. 5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction. 3rd ed. PSIN PLUS, Zurich, Switzerland; 2010." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR53" id="ref-link-section-d413946755e1658">53</a>]); 11-ASC: mean Cronbach’s alpha of 0.83 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Studerus E, Gamma A, Vollenweider FX. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE. 2010;5:e12412 
                https://doi.org/10.1371/journal.pone.0012412
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR52" id="ref-link-section-d413946755e1662">52</a>]). The Mystical Experience Questionnaire, in its latest version the MEQ30 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="MacLean KA, Leoutsakos J-MS, Johnson MW, Griffiths RR. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig. 2012;51:721–37. 
                https://doi.org/10.1111/j.1468-5906.2012.01685.x
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR54" id="ref-link-section-d413946755e1665">54</a>], consists of 30 items assigned to four scales: (1) <i>Mystical</i>, (2) <i>Positive Mood</i>, (3) <i>Transcendence of Time and Space</i>, and (4) <i>Ineffability</i>. This factor structure is currently recommended for analyses and has been assessed for reliability, yielding good scores for all four subscales (Cronbach’s alpha: 0.80–0.95) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Barrett FS, Griffiths RR. The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016. Hum Psychopharmacol. 2017;32:1 
                https://doi.org/10.1002/hup.2564
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR55" id="ref-link-section-d413946755e1681">55</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol (Oxf). 2015;29:1182–90. 
                https://doi.org/10.1177/0269881115609019
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR56" id="ref-link-section-d413946755e1684">56</a>]. A more detailed description of the questionnaires can be found in Schmidt and Majić (2016) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Schmidt TT, Majić T. Empirische Untersuchung veränderter Bewusstseinszustände. Handb. Psychoaktive Subst., Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. 
                https://doi.org/10.1007/978-3-642-55214-4_65-1
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR19" id="ref-link-section-d413946755e1687">19</a>], Majić et al. (2015) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol (Oxf). 2015;29:241–53. 
                https://doi.org/10.1177/0269881114568040
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR9" id="ref-link-section-d413946755e1690">9</a>], and in a recent review by de Deus Pontual et al. (2022) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D. Systematic Review of Psychometric Instruments Used in Research with Psychedelics. J Psychoactive Drugs. 2022 May 26:1–10. 
                https://doi.org/10.1080/02791072.2022.2079108
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR21" id="ref-link-section-d413946755e1693">21</a>].</p><h3 id="Sec5">Statistical analyses</h3><p>We performed meta-regression analyses using restricted cubic splines. A restricted cubic spline model is non-linear and consists of a series of piecewise cubic polynomials that are connected at the position of the knots, with a linear curve before the first and after the last knot [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Stone CJ, Koo C-Y. Additive Splines in Statistics. American Statistical Association, Washington DC. 1985." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR57" id="ref-link-section-d413946755e1704">57</a>]. It was suggested that four or five knots are usually adequate to fully capture the underlying shape, provided the amount of included studies is sufficiently large [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Harrell FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198–202. 
                https://doi.org/10.1093/jnci/80.15.1198
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR58" id="ref-link-section-d413946755e1707">58</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Harrell FE. Multivariable Modeling Strategies. In: Harrell Jr Frank E, editor. Regres. Model. Strateg. Appl. Linear Models Logist. Ordinal Regres. Surviv. Anal., Cham: Springer International Publishing; 2015. p. 63–102. 
                https://doi.org/10.1007/978-3-319-19425-7_4
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR59" id="ref-link-section-d413946755e1710">59</a>]. Given the limited number of available studies for the 5D-ASC and MEQ30, we chose three knots for those questionnaire-data and 4 knots for the 11-ASC. To account for repeated measures and potential heteroscedasticity of error-terms resulting from repeated measurements on the same or similar set of participants, we clustered standard errors at the study level and estimated the cluster-robust variance with the small sample adjustment proposed by Pustejovsky &amp; Tipton (2022) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Pustejovsky JE, Tipton E. Small-Sample Methods for Cluster-Robust Variance Estimation and Hypothesis Testing in Fixed Effects Models. J Bus Econ Stat. 2018;36:672–83. 
                https://doi.org/10.1080/07350015.2016.1247004
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR60" id="ref-link-section-d413946755e1713">60</a>]. We assumed a within-study correlation <i>p</i> = 0.8 for the variance-covariance matrix. The analyses were performed in R version 4.2.2 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 
                https://www.R-project.org/
                
              . 2022." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR61" id="ref-link-section-d413946755e1720">61</a>] with the metafor-package [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48. 
                https://doi.org/10.18637/jss.v036.i03
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR62" id="ref-link-section-d413946755e1723">62</a>] using the restricted cubic spline model from the drc-package [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PLOS ONE. 2015;10:e0146021 
                https://doi.org/10.1371/journal.pone.0146021
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR63" id="ref-link-section-d413946755e1726">63</a>]. Cluster-robust variance was estimated with the clubSandwich-package [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Pustejovsky J. clubSandwich: Cluster-Robust (Sandwich) Variance Estimators with Small-Sample Corrections. R package version 0.5.8.9999. 
                http://jepusto.github.io/clubSandwich/
                
              . 2023." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR64" id="ref-link-section-d413946755e1729">64</a>] in the R robust function. The R-syntax of this analysis is available on GitHub: <a href="https://github.com/TimHirschfeld/doseresponse_LSD">https://github.com/TimHirschfeld/doseresponse_LSD</a>.</p></div></div></section><section data-title="Results"><div id="Sec6-section"><h2 id="Sec6">Results</h2><div id="Sec6-content"><h3 id="Sec7">Data description</h3><p>Sixteen studies assessing the effects of LSD were included in this analysis, with overall 765 LSD applications. Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://www.nature.com/articles/s41386-023-01588-2#Tab1">1</a> contains a summary of studies included in this analysis. From the 11-ASC, 31 questionnaire datasets from 15 participant samples were included in the analysis; from the 5D-ASC, 18 datasets from nine samples were included; and from the MEQ30, 16 datasets from eight samples were included. Included studies assessed LSD doses ranging from 4 to 200 μg LSD base.</p><h3 id="Sec8">Dose-response analyses</h3><p>Radar charts for each questionnaire and dose-response relationships for each factor and scale of the respective questionnaires are presented in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://www.nature.com/articles/s41386-023-01588-2#Fig1">1</a> (5D-ASC and 11-ASC) and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://www.nature.com/articles/s41386-023-01588-2#Fig2">2</a> (MEQ30). LSD dose-dependently increased effect estimates on all factors and scales of the applied questionnaires. For data exploration and exact dose-effect-determination, the results and summary statistics of this analysis can be accessed via this interactive web-application: <a href="https://dose-response-lsd.asdb.info/">https://dose-response-lsd.asdb.info/</a>.</p><div data-test="figure" data-container-section="figure" id="figure-1" data-title="Dose-response relationships for the Altered States of Consciousness Rating Scale."><figure><figcaption><b id="Fig1" data-test="figure-caption-text">Fig. 1: Dose-response relationships for the Altered States of Consciousness Rating Scale.</b></figcaption><div><div><a data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="https://www.nature.com/articles/s41386-023-01588-2/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41386-023-01588-2/MediaObjects/41386_2023_1588_Fig1_HTML.png?as=webp"/><img aria-describedby="Fig1" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41386-023-01588-2/MediaObjects/41386_2023_1588_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="845"/></picture></a></div><p><b>A</b> Dose-specific subjective effects of LSD measured with the Altered States of Consciousness Rating Scale, in which questionnaire items are organized into five factors, called ‘dimensions’ of altered states of consciousness experiences (5D-ASC). <b>B</b> A finer-grained quantification of specific aspects of subjective experiences is obtained when the questionnaire is analyzed according to the 11-factors schema. These 11 factors can be considered subscales of the three core dimensions of the 5D-ASC (see corresponding colors of the subscale names). Doses are given in microgram, as absolute doses not normalized to body weight; effects are given as the percentage score of the maximum score on each factor (questionnaire items were anchored with 0% for ‘No, not more than usual’ and 100% for ‘Yes, much more than usual’). Circle color indicates from which article the data was obtained; the same color of two circles indicates statistically dependent data. Circle size corresponds to the weight of a study based on study variance (see Methods). Radar charts present the estimated dose-responses for doses up to 200 μg. The color of individual scales corresponds to the primary dimensions and the respective subscales.</p></div></figure></div><div data-test="figure" data-container-section="figure" id="figure-2" data-title="Dose-response relationships for the MEQ30."><figure><figcaption><b id="Fig2" data-test="figure-caption-text">Fig. 2: Dose-response relationships for the MEQ30.</b></figcaption><div><div><a data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="https://www.nature.com/articles/s41386-023-01588-2/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41386-023-01588-2/MediaObjects/41386_2023_1588_Fig2_HTML.png?as=webp"/><img aria-describedby="Fig2" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41386-023-01588-2/MediaObjects/41386_2023_1588_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="441"/></picture></a></div><p>Dose-specific subjective effects of LSD measured with the Mystical Experience Questionnaire (MEQ30). Absolute doses are given in microgram. Effects on the MEQ30 are presented as the percentage score of the maximum score. Circle color indicates from which article the data was obtained; the same color of two circles indicates statistically dependent data. Circle size corresponds to the weight of the data based on study variance (see Methods). Radar charts present the estimated dose-responses for doses up to 200 μg.</p></div></figure></div></div></div></section><section data-title="Discussion"><div id="Sec9-section"><h2 id="Sec9">Discussion</h2><div id="Sec9-content"><p>A meta-analysis on psychometric data was performed to estimate dose-response relationships of subjective effects of LSD. The analysis included data from applications of doses from 4 to 200 μg LSD base, in healthy and clinical study participants. Given that the data is based on retrospective subjective reports relying on introspection, we did not employ assumptions on the specific shape of the fitted model (e.g., not applying a linear or a sigmoidal model); instead, we opted for fitting restricted cubic splines that allow for flexible model fits. Most of the fitted dose-response functions closely resemble sigmoid curves, which is expected and plausible for biophysiological processes. We established robust dose-response relationships, in which LSD dose increased effects on all scales and factors of the included questionnaires. On the 5D- and 11-ASC, the strongest dose-modulation was found for items referring to changes in perception and imagination <i>(Visionary Restructuralization, Changed Meaning of Percepts)</i> as well as positively experienced dissolution of boundaries between self and surroundings (<i>Oceanic Boundlessness</i>), whereas <i>Anxiety</i>, <i>Auditory Alterations</i> and <i>Dread of Ego Dissolution</i> were barely modulated. On the MEQ30, the strongest dose-modulation was found for <i>Ineffability</i> and the weakest for <i>Mystical</i>.</p><p>Most factors and scales exhibit a sigmoid-like shape of dose-effects that either flattens out or reaches a plateau at around 100 μg, while scales and factors with relatively small dose-modulation (<i>Auditory Alterations, Dread of Ego-Dissolution, Anxiety)</i> increase rather linearly. This is in line with a dose-response, within-subject study by Holze et al. (2021) that found similar rating scores for 100 µg and 200 µg for <i>Blissful State</i>, <i>Insightfulness</i>, and <i>Changed Meaning of Percepts</i> [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e1866">28</a>], but significantly higher rating scores for 200 µg compared to 100 µg on the scale <i>Dread of Ego Dissolution</i> (reflecting disembodiment and fear) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e1873">28</a>], indicating a ceiling effect regarding positive subjective effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol. Cham: Springer International Publishing; 2022. p. 3–21. 
                https://doi.org/10.1007/7854_2021_270
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR65" id="ref-link-section-d413946755e1876">65</a>]. Despite considerable variability of effects, the present meta-analysis supports the suggestion that doses between 50 and 100 µg LSD base induce substantial psychological effects in most subjects—a dose range currently used in most clinical trials for therapeutic applications [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol. Cham: Springer International Publishing; 2022. p. 3–21. 
                https://doi.org/10.1007/7854_2021_270
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR65" id="ref-link-section-d413946755e1879">65</a>]. Accordingly, a dose of about 100 μg LSD base most likely induces a pattern of subjective experiences that resembles what is often called a “(full) psychedelic experience”, while the likelihood of adverse reactions is kept low. Please note that the term “psychedelic experiences/state” is not used consistently and no agreement on defining criteria of a psychedelic experience have been settled on.</p><p>LSD doses below 10 μg [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol. Cham: Springer International Publishing; 2022. p. 3–21. 
                https://doi.org/10.1007/7854_2021_270
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR65" id="ref-link-section-d413946755e1885">65</a>] or 20 μg [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706 
                https://doi.org/10.1016/j.neubiorev.2022.104706
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR24" id="ref-link-section-d413946755e1888">24</a>] have previously been proposed as the “microdosing” range of LSD. The fitted curves in our analysis show an onset of effects below 20 μg LSD base. For instance, visual phenomena (11-ASC: <i>Audio-Visual Synesthesia</i>, <i>Complex</i> and <i>Elementary Imagery)</i> show an <i>x</i>-axis intercept at around 10 μg, and at 20 μg reach around 10% of the maximum score. These effects are unlikely due to placebo effects, as those of the given studies which included a placebo condition reported only negligible effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e1904">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;41:81–91. 
                https://doi.org/10.1016/j.euroneuro.2020.10.002
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR26" id="ref-link-section-d413946755e1907">26</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e1910">28</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol CB. 2017;27:451–7. 
                https://doi.org/10.1016/j.cub.2016.12.030
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR35" id="ref-link-section-d413946755e1913">35</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e1916">39</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacol (Berl). 2021. 
                https://doi.org/10.1007/s00213-021-05991-9
                
              ." href="#ref-CR43" id="ref-link-section-d413946755e1920">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019;86:792–800. 
                https://doi.org/10.1016/j.biopsych.2019.05.019
                
              ." href="#ref-CR44" id="ref-link-section-d413946755e1920_1">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143 
                https://doi.org/10.1111/adb.13143
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR45" id="ref-link-section-d413946755e1923">45</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379–90. 
                https://doi.org/10.1017/S0033291715002901
                
              ." href="#ref-CR66" id="ref-link-section-d413946755e1926">66</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2020;45:462–71. 
                https://doi.org/10.1038/s41386-019-0569-3
                
              ." href="#ref-CR67" id="ref-link-section-d413946755e1926_1">67</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Wießner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, Tófoli LF. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2021;53:1–15. 
                https://doi.org/10.1017/S0033291721002531
                
              ." href="#ref-CR68" id="ref-link-section-d413946755e1926_2">68</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93:215–23. 
                https://doi.org/10.1016/j.biopsych.2022.08.025
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR69" id="ref-link-section-d413946755e1929">69</a>]. However, these estimates are strongly influenced by the fact that multiple studies investigated doses below 20 μg, while there are no studies available in the dose range from 20 to 50 μg, resulting in an overestimation of the curves slope at their onset. Most studies below 20 μg effectively show null-effects and make the microdosing range of 0–20 μg plausible, but more data is needed to determine the average onset of effects more precisely.</p><p>A recent systematic review indicates a mediating role of mystical-type experiences for treatment outcomes of psychedelic therapy [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70" title="Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry. 2022;13:917199. 
                https://doi.org/10.3389/fpsyt.2022.917199
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR70" id="ref-link-section-d413946755e1935">70</a>], so special attention is drawn on the dose range to predict such experiences. Barrett et al. (2015) suggest that complete mystical-type experiences are reached with scores of ≥60% on each of the four factors of the MEQ30 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol (Oxf). 2015;29:1182–90. 
                https://doi.org/10.1177/0269881115609019
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR56" id="ref-link-section-d413946755e1938">56</a>]. Applying this criterion, the present analysis suggests that such experiences are rather unlikely to occur in the given dose range. Similarly, Liechti et al. (2017) report that full mystical-type experiences occur rather rarely at LSD doses of 200 μg. The authors suggest that mystical-type and spiritual experiences might highly depend on participant characteristics and experimental setting [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e1941">39</a>], which might explain that 25% and 35% of participants in a study by Family et al. (2022) met criteria for a full mystical experience after 50 µg and 100 µg, respectively [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, et al. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol (Oxf). 2022;36:321–36. 
                https://doi.org/10.1177/02698811211069103
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR71" id="ref-link-section-d413946755e1944">71</a>]. However, considering the results of the MEQ30 factors determined in this meta-analysis, datapoints of mentioned study partially lie outside or in the margins of the calculated confidence intervals and thus may not reflect general outcomes. Overall, full mystical-type experiences seem unlikely to be induced with doses below 200 µg and their occurrence appears to be strongly influenced by non-pharmacological factors. Targeted therapeutic implementation of other factors than dose need to be further investigated.</p><p>Non-pharmacological factors that influence psychedelic experiences are often categorized in set (participant personality and preparation and expectation of substance use) and setting (environment of substance administration) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Zinberg NE. Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. New Haven CT, Yale University Press; 1984." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR30" id="ref-link-section-d413946755e1951">30</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72" title="Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law. 2017;3:2050324516683325. 
                https://doi.org/10.1177/2050324516683325
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR72" id="ref-link-section-d413946755e1954">72</a>] and are thought to lead to considerable inter- and intra-individual variability of subjective effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 73" title="Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS. States and traits related to the quality and consequences of psychedelic experiences. Psychol Conscious Theory Res Pr. 2019;6:1–21. 
                https://doi.org/10.1037/cns0000169
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR73" id="ref-link-section-d413946755e1957">73</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 74" title="Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting Responses to Psychedelics: A Prospective Study. Front Pharm. 2018;9:897. 
                https://doi.org/10.3389/fphar.2018.00897
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR74" id="ref-link-section-d413946755e1960">74</a>]. The studies included in our analysis vary greatly with regard to experimental setting. Bershad et al. (2019) reports of “living-room style” environments with possibilities to relax, read or watch movies between measurements [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019;86:792–800. 
                https://doi.org/10.1016/j.biopsych.2019.05.019
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR44" id="ref-link-section-d413946755e1963">44</a>], similar to Preller et al. (2017) (“in an aesthetic living-room-like room”) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol CB. 2017;27:451–7. 
                https://doi.org/10.1016/j.cub.2016.12.030
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR35" id="ref-link-section-d413946755e1967">35</a>] and de Wit et al. (2022) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143 
                https://doi.org/10.1111/adb.13143
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR45" id="ref-link-section-d413946755e1970">45</a>]. In other studies, however, participants were also given tasks during LSD applications that involved greater effort, potentially inhibiting the manifestation of certain effects [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 75" title="Savage C. The resolution and subsequent remobilization of resistance by LSD in psychotherapy. J Nerv Ment Dis. 1957;125:434–7. 
                https://doi.org/10.1097/00005053-195707000-00015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR75" id="ref-link-section-d413946755e1973">75</a>]. Previous work indicated that spatially constrained neuroimaging procedures may be demanding for some individuals and could increase the likelihood of challenging experiences [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol Oxf Engl. 2011;25:1434–52. 
                https://doi.org/10.1177/0269881110382466
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR17" id="ref-link-section-d413946755e1976">17</a>]. Carhart-Harris et al. (2016) reported on fMRI and MEG measurements of over 60 min each, as well as previous MRI environment habituation and a subsequent battery of cognitive and behavioral tests [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379–90. 
                https://doi.org/10.1017/S0033291715002901
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR66" id="ref-link-section-d413946755e1979">66</a>]. From the studies included, also Holze et al. (2020) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2020;45:462–71. 
                https://doi.org/10.1038/s41386-019-0569-3
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR67" id="ref-link-section-d413946755e1982">67</a>] and Liechti et al. (2017) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e1986">39</a>] (fMRI data published in Müller et al., (2017) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Müller F, Lenz C, Dolder P, Lang U, Schmidt A, Liechti M, et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand. 2017;136:648–57. 
                https://doi.org/10.1111/acps.12818
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR41" id="ref-link-section-d413946755e1989">41</a>]) reported of fMRI measurements during the experimental session. Schmid et al. (2015) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e1992">22</a>], Liechti et al. (2017) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. 
                https://doi.org/10.1007/s00213-016-4453-0
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR39" id="ref-link-section-d413946755e1995">39</a>], Holze et al. (2021 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e1998">28</a>], 2022 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7. 
                https://doi.org/10.1038/s41386-022-01297-2
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR5" id="ref-link-section-d413946755e2001">5</a>]) reported on “quiet standard hospital patient room” environments, and the study procedure by Family et al. (2022) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, et al. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol (Oxf). 2022;36:321–36. 
                https://doi.org/10.1177/02698811211069103
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR71" id="ref-link-section-d413946755e2005">71</a>] included a 60 min breathing exercise. Additional factors influencing the psychedelic experience and thereby increasing the variability within and between the given datasets may involve the subject’s age, previous experience with psychedelics or other mind-altering substances, as well as differences in individual pharmacokinetics [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76" title="Lewis CR, Preller KH, Braden BB, Riecken C, Vollenweider FX. Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. Biomedicines. 2020;8:34. 
                https://doi.org/10.3390/biomedicines8020034
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR76" id="ref-link-section-d413946755e2008">76</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 77" title="Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep. 2021;11:10851. 
                https://doi.org/10.1038/s41598-021-90343-y
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR77" id="ref-link-section-d413946755e2011">77</a>]. The study by Family et al. (2022) for instance reports of applications of 50 µg LSD to predominantly (9 of 12) psychedelic-naïve participants, as well as 75 and 100 µg LSD to psychedelic-non-naïve participants. They report of higher questionnaire ratings on all factors of the 5D-ASC and MEQ30 in the (naïve) 50 µg cohort compared to the (non-naïve) 75 µg cohort, as well as higher ratings on most factors in the (naïve) 50 µg cohort compared to the (non-naïve) 100 µg cohort [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, et al. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol (Oxf). 2022;36:321–36. 
                https://doi.org/10.1177/02698811211069103
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR71" id="ref-link-section-d413946755e2014">71</a>]. The study by Wießner et al. (2021) also reports relatively high 11-ASC scores (especially for the factors <i>Insightfulness</i>, <i>Spiritual Experience</i>, <i>Blissful State</i>, and <i>Complex Imaginary</i>) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Wießner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, Tófoli LF. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2021;53:1–15. 
                https://doi.org/10.1017/S0033291721002531
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR68" id="ref-link-section-d413946755e2030">68</a>] compared to other studies on the same LSD dose included in this analysis. This may result from relatively high lifetime use of other psychedelics or mind-altering substances among study participants (particularly ayahuasca, with a mean lifetime use of 69 ± 131 S.D.) and the fact that most participants (67%) identify themselves as spiritual. Other studies, however, have not observed any differences in subjective effects between experienced and non-experienced LSD users when compared within the same study [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7. 
                https://doi.org/10.1038/s41386-022-01297-2
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR5" id="ref-link-section-d413946755e2033">5</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. 
                https://doi.org/10.1016/j.biopsych.2014.11.015
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR22" id="ref-link-section-d413946755e2036">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. 
                https://doi.org/10.1038/s41386-020-00883-6
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR28" id="ref-link-section-d413946755e2039">28</a>]. Therefore, differences in extra-pharmacological factors likely led to the observed variance in the ratings of subjective experiences. The confidence intervals of the present study can yield as data-driven estimates for the expected variability of experiences, also in clinical samples (Note: The confidence intervals refer to the mean group effects, while the variance across participants can be substantially higher). Interestingly, factors assessing alterations of visual perception and cognitive abilities exhibit less variability (smaller CI range) than factors assessing experiences of unity, blissful state, and spirituality. This could be due to their highly personal character, which might be stronger influenced by non-pharmacological factors. Alternatively, variability might stem from less reliable assessment of these high-order concepts as compared to factors assessing perceptual alterations. Future studies with a more comparable assessment of non-pharmacological factors are needed to allow for systematic investigation of their exact contributions in shaping subjective experiences.</p><p>Further limitations should be considered when using the analysis at hand to determine LSD doses. First, administration methods varied across studies. Most studies administered LSD orally as capsules, while it was administered sublingually in two studies [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019;86:792–800. 
                https://doi.org/10.1016/j.biopsych.2019.05.019
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR44" id="ref-link-section-d413946755e2045">44</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143 
                https://doi.org/10.1111/adb.13143
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR45" id="ref-link-section-d413946755e2048">45</a>] and intravenously in one study [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379–90. 
                https://doi.org/10.1017/S0033291715002901
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR66" id="ref-link-section-d413946755e2051">66</a>]. Moreover, LSD formulations differed across studies: most studies applied LSD base (or provided the dose calculated for LSD base), while some doses referred to LSD salt in the form of LSD tartrate—the typical formulation sold on the black market. No direct experimental comparison of the bioequivalence of the two formulations has been made to date. We transformed doses according to Holze et al. (2021) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Holze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clin Pharm Ther. 2021;109:658–66. 
                https://doi.org/10.1002/cpt.2057
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR46" id="ref-link-section-d413946755e2054">46</a>], who suggested that 1 µg of LSD base corresponds to ~1.46 µg of 1:1 LSD tartrate or 1.23–1.33 µg 2:1 LSD tartrate, depending on the salt form and amount of crystal water [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol. Cham: Springer International Publishing; 2022. p. 3–21. 
                https://doi.org/10.1007/7854_2021_270
                
              ." href="https://www.nature.com/articles/s41386-023-01588-2#ref-CR65" id="ref-link-section-d413946755e2057">65</a>]. Moreover, the results reflect estimates on the variability of average effects in study samples based on doses of up to 200 µg, so the experiences of individual subjects may differ considerably. Finally, it should be noted that study samples are usually comprised of highly selected and well-prepared participants. For these reasons and because the quality and quantity of recreationally used products is often unclear, the present results do not necessarily apply to the general population or to recreational use outside controlled laboratory or therapeutic settings.</p><p>In conclusion, the present meta-analysis on subjective effects of LSD in study participants revealed dose-dependent alterations of consciousness with substantial heterogeneity of effects across laboratory and therapeutic settings on all scales and factors assessed by given questionnaires. The strongest dose-modulation was found for perceptual and imaginative changes followed by positively experienced dissolution of boundaries between self and surroundings with a limited spiritual or mystical-type character in the given dosage range. Dose-response relationships resemble sigmoid functions on most factors and scales of the questionnaires, with an observable ceiling effect at circa 100 μg LSD base. Results may be used as a general reference to relate observed with expected dose-specific effects.</p></div></div></section>
                </div>
            

            <div>
            <div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div id="Bib1-section"><h2 id="Bib1">References</h2><div id="Bib1-content"><div data-container-section="references"><ol data-track-component="outbound reference"><li data-counter="1."><p id="ref-CR1">Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897–902. <a href="https://doi.org/10.1097/00001756-199812010-00024">https://doi.org/10.1097/00001756-199812010-00024</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/00001756-199812010-00024" data-track-action="article reference" href="https://doi.org/10.1097%2F00001756-199812010-00024" aria-label="Article reference 1" data-doi="10.1097/00001756-199812010-00024">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXjtVCitQ%3D%3D" aria-label="CAS reference 1">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9875725" aria-label="PubMed reference 1">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Psilocybin%20induces%20schizophrenia-like%20psychosis%20in%20humans%20via%20a%20serotonin-2%20agonist%20action&amp;journal=NeuroReport.&amp;doi=10.1097%2F00001756-199812010-00024&amp;volume=9&amp;pages=3897-902&amp;publication_year=1998&amp;author=Vollenweider%2CFX&amp;author=Vollenweider-Scherpenhuyzen%2CMFI&amp;author=B%C3%A4bler%2CA&amp;author=Vogel%2CH&amp;author=Hell%2CD">
                    Google Scholar</a> 
                </p></li><li data-counter="2."><p id="ref-CR2">Nichols DE. Chemistry and Structure–Activity Relationships of Psychedelics. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behav. Neurobiol. Psychedelic Drugs, vol. 36, Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. p. 1–43. <a href="https://doi.org/10.1007/7854_2017_475">https://doi.org/10.1007/7854_2017_475</a>.</p></li><li data-counter="3."><p id="ref-CR3">Nichols DE. Psychedelics. Pharm Rev. 2016;68:264–355. <a href="https://doi.org/10.1124/pr.115.011478">https://doi.org/10.1124/pr.115.011478</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1124/pr.115.011478" data-track-action="article reference" href="https://doi.org/10.1124%2Fpr.115.011478" aria-label="Article reference 3" data-doi="10.1124/pr.115.011478">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXlsVCltrg%3D" aria-label="CAS reference 3">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26841800" aria-label="PubMed reference 3">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=&amp;journal=Psychedelics.%20Pharm%20Rev.&amp;doi=10.1124%2Fpr.115.011478&amp;volume=68&amp;pages=264-355&amp;publication_year=2016&amp;author=Nichols%2CDE">
                    Google Scholar</a> 
                </p></li><li data-counter="4."><p id="ref-CR4">Hartman AM, Hollister LE. Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia. 1963;4:441–51. <a href="https://doi.org/10.1007/BF00403349">https://doi.org/10.1007/BF00403349</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/BF00403349" data-track-action="article reference" href="https://doi.org/10.1007%2FBF00403349" aria-label="Article reference 4" data-doi="10.1007/BF00403349">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaF2c%2Fgs1Wmsw%3D%3D" aria-label="CAS reference 4">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14048565" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20mescaline%2C%20lysergic%20acid%20diethylamide%20and%20psilocybin%20on%20color%20perception&amp;journal=Psychopharmacologia&amp;doi=10.1007%2FBF00403349&amp;volume=4&amp;pages=441-51&amp;publication_year=1963&amp;author=Hartman%2CAM&amp;author=Hollister%2CLE">
                    Google Scholar</a> 
                </p></li><li data-counter="5."><p id="ref-CR5">Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7. <a href="https://doi.org/10.1038/s41386-022-01297-2">https://doi.org/10.1038/s41386-022-01297-2</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41386-022-01297-2" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41386-022-01297-2" aria-label="Article reference 5" data-doi="10.1038/s41386-022-01297-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XmsF2nt7s%3D" aria-label="CAS reference 5">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35217796" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018810" aria-label="PubMed Central reference 5">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Direct%20comparison%20of%20the%20acute%20effects%20of%20lysergic%20acid%20diethylamide%20and%20psilocybin%20in%20a%20double-blind%20placebo-controlled%20study%20in%20healthy%20subjects&amp;journal=Neuropsychopharmacology&amp;doi=10.1038%2Fs41386-022-01297-2&amp;volume=47&amp;pages=1180-7&amp;publication_year=2022&amp;author=Holze%2CF&amp;author=Ley%2CL&amp;author=M%C3%BCller%2CF&amp;author=Becker%2CAM&amp;author=Straumann%2CI&amp;author=Vizeli%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="6."><p id="ref-CR6">Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962;3:219–23. <a href="https://doi.org/10.1007/BF00412109">https://doi.org/10.1007/BF00412109</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/BF00412109" data-track-action="article reference" href="https://doi.org/10.1007%2FBF00412109" aria-label="Article reference 6" data-doi="10.1007/BF00412109">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaF2cXjsVWrtw%3D%3D" aria-label="CAS reference 6">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14007905" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Comparison%20of%20psilocin%20with%20psilocybin%2C%20mescaline%20and%20LSD-25&amp;journal=Psychopharmacologia&amp;doi=10.1007%2FBF00412109&amp;volume=3&amp;pages=219-23&amp;publication_year=1962&amp;author=Wolbach%2CAB&amp;author=Miner%2CEJ&amp;author=Isbell%2CH">
                    Google Scholar</a> 
                </p></li><li data-counter="7."><p id="ref-CR7">Shulgin AT, Shulgin A. Tihkal: the continuation. Berkeley:Transform; 1997.</p></li><li data-counter="8."><p id="ref-CR8">Hofmann A. LSD, my problem child and insights/outlooks. Beckley Foundation. Oxford University Press; 2013.</p></li><li data-counter="9."><p id="ref-CR9">Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol (Oxf). 2015;29:241–53. <a href="https://doi.org/10.1177/0269881114568040">https://doi.org/10.1177/0269881114568040</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881114568040" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881114568040" aria-label="Article reference 9" data-doi="10.1177/0269881114568040">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXlt1Khsrk%3D" aria-label="CAS reference 9">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Peak%20experiences%20and%20the%20afterglow%20phenomenon%3A%20When%20and%20how%20do%20therapeutic%20effects%20of%20hallucinogens%20depend%20on%20psychedelic%20experiences%3F&amp;journal=J%20Psychopharmacol%20%28Oxf%29.&amp;doi=10.1177%2F0269881114568040&amp;volume=29&amp;pages=241-53&amp;publication_year=2015&amp;author=Maji%C4%87%2CT&amp;author=Schmidt%2CTT&amp;author=Gallinat%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="10."><p id="ref-CR10">Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642–51. <a href="https://doi.org/10.1038/nrn2884">https://doi.org/10.1038/nrn2884</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nrn2884" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrn2884" aria-label="Article reference 10" data-doi="10.1038/nrn2884">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVCmtLnO" aria-label="CAS reference 10">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20717121" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20neurobiology%20of%20psychedelic%20drugs%3A%20implications%20for%20the%20treatment%20of%20mood%20disorders&amp;journal=Nat%20Rev%20Neurosci.&amp;doi=10.1038%2Fnrn2884&amp;volume=11&amp;pages=642-51&amp;publication_year=2010&amp;author=Vollenweider%2CFX&amp;author=Kometer%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="11."><p id="ref-CR11">Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24. <a href="https://doi.org/10.1038/s41583-020-0367-2">https://doi.org/10.1038/s41583-020-0367-2</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41583-020-0367-2" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41583-020-0367-2" aria-label="Article reference 11" data-doi="10.1038/s41583-020-0367-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVanu77F" aria-label="CAS reference 11">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32929261" aria-label="PubMed reference 11">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychedelic%20drugs%3A%20neurobiology%20and%20potential%20for%20treatment%20of%20psychiatric%20disorders&amp;journal=Nat%20Rev%20Neurosci.&amp;doi=10.1038%2Fs41583-020-0367-2&amp;volume=21&amp;pages=611-24&amp;publication_year=2020&amp;author=Vollenweider%2CFX&amp;author=Preller%2CKH">
                    Google Scholar</a> 
                </p></li><li data-counter="12."><p id="ref-CR12">Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (Oxf). 2012;26:994–1002. <a href="https://doi.org/10.1177/0269881112439253">https://doi.org/10.1177/0269881112439253</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881112439253" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881112439253" aria-label="Article reference 12" data-doi="10.1177/0269881112439253">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhs1OltbfN" aria-label="CAS reference 12">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Lysergic%20acid%20diethylamide%20%28LSD%29%20for%20alcoholism%3A%20meta-analysis%20of%20randomized%20controlled%20trials&amp;journal=J%20Psychopharmacol%20%28Oxf%29.&amp;doi=10.1177%2F0269881112439253&amp;volume=26&amp;pages=994-1002&amp;publication_year=2012&amp;author=Krebs%2CTS&amp;author=Johansen%2CP-%C3%98">
                    Google Scholar</a> 
                </p></li><li data-counter="13."><p id="ref-CR13">Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:1–10. <a href="https://doi.org/10.1016/j.pnpbp.2017.09.012">https://doi.org/10.1016/j.pnpbp.2017.09.012</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.pnpbp.2017.09.012" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.pnpbp.2017.09.012" aria-label="Article reference 13" data-doi="10.1016/j.pnpbp.2017.09.012">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsFyqtrjK" aria-label="CAS reference 13">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28947181" aria-label="PubMed reference 13">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Serotonergic%20hallucinogens%20in%20the%20treatment%20of%20anxiety%20and%20depression%20in%20patients%20suffering%20from%20a%20life-threatening%20disease%3A%20A%20systematic%20review&amp;journal=Prog%20Neuropsychopharmacol%20Biol%20Psychiatry.&amp;doi=10.1016%2Fj.pnpbp.2017.09.012&amp;volume=81&amp;pages=1-10&amp;publication_year=2018&amp;author=Reiche%2CS&amp;author=Hermle%2CL&amp;author=Gutwinski%2CS&amp;author=Jungaberle%2CH&amp;author=Gasser%2CP&amp;author=Maji%C4%87%2CT">
                    Google Scholar</a> 
                </p></li><li data-counter="14."><p id="ref-CR14">Evens R, Reiche S, Marek RM, Moon DU, Groß RE, Romanello A, et al. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey. Front Psychiatry. 2021;12:732028 <a href="https://doi.org/10.3389/fpsyt.2021.732028">https://doi.org/10.3389/fpsyt.2021.732028</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fpsyt.2021.732028" data-track-action="article reference" href="https://doi.org/10.3389%2Ffpsyt.2021.732028" aria-label="Article reference 14" data-doi="10.3389/fpsyt.2021.732028">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34803757" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599818" aria-label="PubMed Central reference 14">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychedelic%20Experiences%20During%20the%20Early%20COVID-19%20Pandemic%3A%20Findings%20From%20an%20International%20Online%20Survey&amp;journal=Front%20Psychiatry.&amp;doi=10.3389%2Ffpsyt.2021.732028&amp;volume=12&amp;publication_year=2021&amp;author=Evens%2CR&amp;author=Reiche%2CS&amp;author=Marek%2CRM&amp;author=Moon%2CDU&amp;author=Gro%C3%9F%2CRE&amp;author=Romanello%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="15."><p id="ref-CR15">Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2022:S0006322322015530. <a href="https://doi.org/10.1016/j.biopsych.2022.08.025">https://doi.org/10.1016/j.biopsych.2022.08.025</a>.</p></li><li data-counter="16."><p id="ref-CR16">Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. J Nerv Ment Dis. 2014;202:513–20. <a href="https://doi.org/10.1097/NMD.0000000000000113">https://doi.org/10.1097/NMD.0000000000000113</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/NMD.0000000000000113" data-track-action="article reference" href="https://doi.org/10.1097%2FNMD.0000000000000113" aria-label="Article reference 16" data-doi="10.1097/NMD.0000000000000113">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24594678" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086777" aria-label="PubMed Central reference 16">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20Efficacy%20of%20Lysergic%20Acid%20Diethylamide-Assisted%20Psychotherapy%20for%20Anxiety%20Associated%20With%20Life-threatening%20Diseases&amp;journal=J%20Nerv%20Ment%20Dis.&amp;doi=10.1097%2FNMD.0000000000000113&amp;volume=202&amp;pages=513-20&amp;publication_year=2014&amp;author=Gasser%2CP&amp;author=Holstein%2CD&amp;author=Michel%2CY&amp;author=Doblin%2CR&amp;author=Yazar-Klosinski%2CB&amp;author=Passie%2CT">
                    Google Scholar</a> 
                </p></li><li data-counter="17."><p id="ref-CR17">Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol Oxf Engl. 2011;25:1434–52. <a href="https://doi.org/10.1177/0269881110382466">https://doi.org/10.1177/0269881110382466</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881110382466" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881110382466" aria-label="Article reference 17" data-doi="10.1177/0269881110382466">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XmsFGgtg%3D%3D" aria-label="CAS reference 17">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Acute%2C%20subacute%20and%20long-term%20subjective%20effects%20of%20psilocybin%20in%20healthy%20humans%3A%20a%20pooled%20analysis%20of%20experimental%20studies&amp;journal=J%20Psychopharmacol%20Oxf%20Engl.&amp;doi=10.1177%2F0269881110382466&amp;volume=25&amp;pages=1434-52&amp;publication_year=2011&amp;author=Studerus%2CE&amp;author=Kometer%2CM&amp;author=Hasler%2CF&amp;author=Vollenweider%2CFX">
                    Google Scholar</a> 
                </p></li><li data-counter="18."><p id="ref-CR18">Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharm Transl Sci. 2021;4:568–72. <a href="https://doi.org/10.1021/acsptsci.0c00194">https://doi.org/10.1021/acsptsci.0c00194</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1021/acsptsci.0c00194" data-track-action="article reference" href="https://doi.org/10.1021%2Facsptsci.0c00194" aria-label="Article reference 18" data-doi="10.1021/acsptsci.0c00194">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFeqsbjI" aria-label="CAS reference 18">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Subjective%20Effects%20of%20Psychedelics%20Are%20Necessary%20for%20Their%20Enduring%20Therapeutic%20Effects&amp;journal=ACS%20Pharm%20Transl%20Sci.&amp;doi=10.1021%2Facsptsci.0c00194&amp;volume=4&amp;pages=568-72&amp;publication_year=2021&amp;author=Yaden%2CDB&amp;author=Griffiths%2CRR">
                    Google Scholar</a> 
                </p></li><li data-counter="19."><p id="ref-CR19">Schmidt TT, Majić T. Empirische Untersuchung veränderter Bewusstseinszustände. Handb. Psychoaktive Subst., Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. <a href="https://doi.org/10.1007/978-3-642-55214-4_65-1">https://doi.org/10.1007/978-3-642-55214-4_65-1</a>.</p></li><li data-counter="20."><p id="ref-CR20">Hirschfeld T, Schmidt TT. Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol (Oxf). 2021;35:384–97. <a href="https://doi.org/10.1177/0269881121992676">https://doi.org/10.1177/0269881121992676</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881121992676" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881121992676" aria-label="Article reference 20" data-doi="10.1177/0269881121992676">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXptFWjsbc%3D" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Dose%E2%80%93response%20relationships%20of%20psilocybin-induced%20subjective%20experiences%20in%20humans&amp;journal=J%20Psychopharmacol%20%28Oxf%29.&amp;doi=10.1177%2F0269881121992676&amp;volume=35&amp;pages=384-97&amp;publication_year=2021&amp;author=Hirschfeld%2CT&amp;author=Schmidt%2CTT">
                    Google Scholar</a> 
                </p></li><li data-counter="21."><p id="ref-CR21">de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D. Systematic Review of Psychometric Instruments Used in Research with Psychedelics. J Psychoactive Drugs. 2022 May 26:1–10. <a href="https://doi.org/10.1080/02791072.2022.2079108">https://doi.org/10.1080/02791072.2022.2079108</a>.</p></li><li data-counter="22."><p id="ref-CR22">Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry. 2015;78:544–53. <a href="https://doi.org/10.1016/j.biopsych.2014.11.015">https://doi.org/10.1016/j.biopsych.2014.11.015</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.biopsych.2014.11.015" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.biopsych.2014.11.015" aria-label="Article reference 22" data-doi="10.1016/j.biopsych.2014.11.015">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtVCruro%3D" aria-label="CAS reference 22">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25575620" aria-label="PubMed reference 22">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Acute%20Effects%20of%20Lysergic%20Acid%20Diethylamide%20in%20Healthy%20Subjects&amp;journal=Biol%20Psychiatry.&amp;doi=10.1016%2Fj.biopsych.2014.11.015&amp;volume=78&amp;pages=544-53&amp;publication_year=2015&amp;author=Schmid%2CY&amp;author=Enzler%2CF&amp;author=Gasser%2CP&amp;author=Grouzmann%2CE&amp;author=Preller%2CKH&amp;author=Vollenweider%2CFX">
                    Google Scholar</a> 
                </p></li><li data-counter="23."><p id="ref-CR23">Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol Oxf Engl. 2015;29:57–68. <a href="https://doi.org/10.1177/0269881114555249">https://doi.org/10.1177/0269881114555249</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881114555249" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881114555249" aria-label="Article reference 23" data-doi="10.1177/0269881114555249">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVGnsbs%3D" aria-label="CAS reference 23">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=LSD-assisted%20psychotherapy%20for%20anxiety%20associated%20with%20a%20life-threatening%20disease%3A%20a%20qualitative%20study%20of%20acute%20and%20sustained%20subjective%20effects&amp;journal=J%20Psychopharmacol%20Oxf%20Engl.&amp;doi=10.1177%2F0269881114555249&amp;volume=29&amp;pages=57-68&amp;publication_year=2015&amp;author=Gasser%2CP&amp;author=Kirchner%2CK&amp;author=Passie%2CT">
                    Google Scholar</a> 
                </p></li><li data-counter="24."><p id="ref-CR24">Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706 <a href="https://doi.org/10.1016/j.neubiorev.2022.104706">https://doi.org/10.1016/j.neubiorev.2022.104706</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.neubiorev.2022.104706" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.neubiorev.2022.104706" aria-label="Article reference 24" data-doi="10.1016/j.neubiorev.2022.104706">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35609684" aria-label="PubMed reference 24">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20emerging%20science%20of%20microdosing%3A%20A%20systematic%20review%20of%20research%20on%20low%20dose%20psychedelics%20%281955-2021%29%20and%20recommendations%20for%20the%20field&amp;journal=Neurosci%20Biobehav%20Rev.&amp;doi=10.1016%2Fj.neubiorev.2022.104706&amp;volume=139&amp;publication_year=2022&amp;author=Polito%2CV&amp;author=Liknaitzky%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="25."><p id="ref-CR25">Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol Oxf Engl. 2016;30:1181–97. <a href="https://doi.org/10.1177/0269881116675513">https://doi.org/10.1177/0269881116675513</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881116675513" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881116675513" aria-label="Article reference 25" data-doi="10.1177/0269881116675513">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVGrur%2FJ" aria-label="CAS reference 25">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Psilocybin%20produces%20substantial%20and%20sustained%20decreases%20in%20depression%20and%20anxiety%20in%20patients%20with%20life-threatening%20cancer%3A%20A%20randomized%20double-blind%20trial&amp;journal=J%20Psychopharmacol%20Oxf%20Engl.&amp;doi=10.1177%2F0269881116675513&amp;volume=30&amp;pages=1181-97&amp;publication_year=2016&amp;author=Griffiths%2CRR&amp;author=Johnson%2CMW&amp;author=Carducci%2CMA&amp;author=Umbricht%2CA&amp;author=Richards%2CWA&amp;author=Richards%2CBD">
                    Google Scholar</a> 
                </p></li><li data-counter="26."><p id="ref-CR26">Hutten NRPW, Mason NL, Dolder PC, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;41:81–91. <a href="https://doi.org/10.1016/j.euroneuro.2020.10.002">https://doi.org/10.1016/j.euroneuro.2020.10.002</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.euroneuro.2020.10.002" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.euroneuro.2020.10.002" aria-label="Article reference 26" data-doi="10.1016/j.euroneuro.2020.10.002">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitFSnsr%2FP" aria-label="CAS reference 26">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Mood%20and%20cognition%20after%20administration%20of%20low%20LSD%20doses%20in%20healthy%20volunteers%3A%20A%20placebo%20controlled%20dose-effect%20finding%20study&amp;journal=Eur%20Neuropsychopharmacol%20J%20Eur%20Coll%20Neuropsychopharmacol.&amp;doi=10.1016%2Fj.euroneuro.2020.10.002&amp;volume=41&amp;pages=81-91&amp;publication_year=2020&amp;author=Hutten%2CNRPW&amp;author=Mason%2CNL&amp;author=Dolder%2CPC">
                    Google Scholar</a> 
                </p></li><li data-counter="27."><p id="ref-CR27">Hutten NRPW, Mason NL, Dolder PC, et al. KPC. Motives and Side-Effects of Microdosing With Psychedelics Among Users. Int J Neuropsychopharmacol. 2019;22:426–34. <a href="https://doi.org/10.1093/ijnp/pyz029">https://doi.org/10.1093/ijnp/pyz029</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/ijnp/pyz029" data-track-action="article reference" href="https://doi.org/10.1093%2Fijnp%2Fpyz029" aria-label="Article reference 27" data-doi="10.1093/ijnp/pyz029">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFCmtbbJ" aria-label="CAS reference 27">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31152167" aria-label="PubMed reference 27">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600464" aria-label="PubMed Central reference 27">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=KPC.%20Motives%20and%20Side-Effects%20of%20Microdosing%20With%20Psychedelics%20Among%20Users&amp;journal=Int%20J%20Neuropsychopharmacol.&amp;doi=10.1093%2Fijnp%2Fpyz029&amp;volume=22&amp;pages=426-34&amp;publication_year=2019&amp;author=Hutten%2CNRPW&amp;author=Mason%2CNL&amp;author=Dolder%2CPC">
                    Google Scholar</a> 
                </p></li><li data-counter="28."><p id="ref-CR28">Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:537–44. <a href="https://doi.org/10.1038/s41386-020-00883-6">https://doi.org/10.1038/s41386-020-00883-6</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41386-020-00883-6" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41386-020-00883-6" aria-label="Article reference 28" data-doi="10.1038/s41386-020-00883-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitFymtr3F" aria-label="CAS reference 28">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Acute%20dose-dependent%20effects%20of%20lysergic%20acid%20diethylamide%20in%20a%20double-blind%20placebo-controlled%20study%20in%20healthy%20subjects&amp;journal=Neuropsychopharmacol%20Publ%20Am%20Coll%20Neuropsychopharmacol.&amp;doi=10.1038%2Fs41386-020-00883-6&amp;volume=46&amp;pages=537-44&amp;publication_year=2021&amp;author=Holze%2CF&amp;author=Vizeli%2CP&amp;author=Ley%2CL&amp;author=M%C3%BCller%2CF&amp;author=Dolder%2CP&amp;author=Stocker%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="29."><p id="ref-CR29">Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, et al. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. J Affect Disord. 2023;326:18–25. <a href="https://doi.org/10.1016/j.jad.2023.01.077">https://doi.org/10.1016/j.jad.2023.01.077</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.jad.2023.01.077" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jad.2023.01.077" aria-label="Article reference 29" data-doi="10.1016/j.jad.2023.01.077">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXitFKmtbs%3D" aria-label="CAS reference 29">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36707036" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimizing%20outcomes%20in%20psilocybin%20therapy%3A%20Considerations%20in%20participant%20evaluation%20and%20preparation&amp;journal=J%20Affect%20Disord.&amp;doi=10.1016%2Fj.jad.2023.01.077&amp;volume=326&amp;pages=18-25&amp;publication_year=2023&amp;author=Modlin%2CNL&amp;author=Miller%2CTM&amp;author=Rucker%2CJJ&amp;author=Kirlic%2CN&amp;author=Lennard-Jones%2CM&amp;author=Schlosser%2CD">
                    Google Scholar</a> 
                </p></li><li data-counter="30."><p id="ref-CR30">Zinberg NE. Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. New Haven CT, Yale University Press; 1984.</p></li><li data-counter="31."><p id="ref-CR31">Schmidt TT, Berkemeyer H. The Altered States Database: Psychometric Data of Altered States of Consciousness. Front Psychol. 2018;9:720 <a href="https://doi.org/10.3389/fpsyg.2018.01028">https://doi.org/10.3389/fpsyg.2018.01028</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fpsyg.2018.01028" data-track-action="article reference" href="https://doi.org/10.3389%2Ffpsyg.2018.01028" aria-label="Article reference 31" data-doi="10.3389/fpsyg.2018.01028">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Altered%20States%20Database%3A%20Psychometric%20Data%20of%20Altered%20States%20of%20Consciousness&amp;journal=Front%20Psychol.&amp;doi=10.3389%2Ffpsyg.2018.01028&amp;volume=9&amp;publication_year=2018&amp;author=Schmidt%2CTT&amp;author=Berkemeyer%2CH">
                    Google Scholar</a> 
                </p></li><li data-counter="32."><p id="ref-CR32">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. <a href="https://doi.org/10.1136/bmj.n71">https://doi.org/10.1136/bmj.n71</a>.</p></li><li data-counter="33."><p id="ref-CR33">Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT. The Altered States Database: Psychometric data from a systematic literature review. Sci Data. 2022;9:720 <a href="https://doi.org/10.1038/s41597-022-01822-4">https://doi.org/10.1038/s41597-022-01822-4</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41597-022-01822-4" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41597-022-01822-4" aria-label="Article reference 33" data-doi="10.1038/s41597-022-01822-4">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36418335" aria-label="PubMed reference 33">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684144" aria-label="PubMed Central reference 33">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Altered%20States%20Database%3A%20Psychometric%20data%20from%20a%20systematic%20literature%20review&amp;journal=Sci%20Data.&amp;doi=10.1038%2Fs41597-022-01822-4&amp;volume=9&amp;publication_year=2022&amp;author=Prugger%2CJ&amp;author=Derdiyok%2CE&amp;author=Dinkelacker%2CJ&amp;author=Costines%2CC&amp;author=Schmidt%2CTT">
                    Google Scholar</a> 
                </p></li><li data-counter="34."><p id="ref-CR34">Peters M, Prugger J, Dimkov P, Schmidt TT. Update of the Altered States Database (ASDB): 2022-12-31. <a href="https://doi.org/10.31234/osf.io/wdfhg.">https://doi.org/10.31234/osf.io/wdfhg.</a> Accessed 02 May 2023.</p></li><li data-counter="35."><p id="ref-CR35">Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol CB. 2017;27:451–7. <a href="https://doi.org/10.1016/j.cub.2016.12.030">https://doi.org/10.1016/j.cub.2016.12.030</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.cub.2016.12.030" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cub.2016.12.030" aria-label="Article reference 35" data-doi="10.1016/j.cub.2016.12.030">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Knsbg%3D" aria-label="CAS reference 35">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28132813" aria-label="PubMed reference 35">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Fabric%20of%20Meaning%20and%20Subjective%20Effects%20in%20LSD-Induced%20States%20Depend%20on%20Serotonin%202A%20Receptor%20Activation&amp;journal=Curr%20Biol%20CB.&amp;doi=10.1016%2Fj.cub.2016.12.030&amp;volume=27&amp;pages=451-7&amp;publication_year=2017&amp;author=Preller%2CKH&amp;author=Herdener%2CM&amp;author=Pokorny%2CT&amp;author=Planzer%2CA&amp;author=Kraehenmann%2CR&amp;author=St%C3%A4mpfli%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="36."><p id="ref-CR36">Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Front Pharm. 2017;8:814 <a href="https://doi.org/10.3389/fphar.2017.00814">https://doi.org/10.3389/fphar.2017.00814</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fphar.2017.00814" data-track-action="article reference" href="https://doi.org/10.3389%2Ffphar.2017.00814" aria-label="Article reference 36" data-doi="10.3389/fphar.2017.00814">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitFems73M" aria-label="CAS reference 36">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=LSD%20Increases%20Primary%20Process%20Thinking%20via%20Serotonin%202A%20Receptor%20Activation&amp;journal=Front%20Pharm.&amp;doi=10.3389%2Ffphar.2017.00814&amp;volume=8&amp;publication_year=2017&amp;author=Kraehenmann%2CR&amp;author=Pokorny%2CD&amp;author=Aicher%2CH&amp;author=Preller%2CKH&amp;author=Pokorny%2CT&amp;author=Bosch%2COG">
                    Google Scholar</a> 
                </p></li><li data-counter="37."><p id="ref-CR37">Schmid Y, Gasser P, Oehen P, Liechti ME. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol Oxf Engl. 2021;35:362–74. <a href="https://doi.org/10.1177/0269881120959604">https://doi.org/10.1177/0269881120959604</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881120959604" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881120959604" aria-label="Article reference 37" data-doi="10.1177/0269881120959604">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXptFWjsbo%3D" aria-label="CAS reference 37">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Acute%20subjective%20effects%20in%20LSD-%20and%20MDMA-assisted%20psychotherapy&amp;journal=J%20Psychopharmacol%20Oxf%20Engl.&amp;doi=10.1177%2F0269881120959604&amp;volume=35&amp;pages=362-74&amp;publication_year=2021&amp;author=Schmid%2CY&amp;author=Gasser%2CP&amp;author=Oehen%2CP&amp;author=Liechti%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="38."><p id="ref-CR38">Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R. Survey of subjective ‘God encounter experiences’: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PloS ONE. 2019;14:e0214377 <a href="https://doi.org/10.1371/journal.pone.0214377">https://doi.org/10.1371/journal.pone.0214377</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0214377" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0214377" aria-label="Article reference 38" data-doi="10.1371/journal.pone.0214377">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFGrtbrN" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31013281" aria-label="PubMed reference 38">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478303" aria-label="PubMed Central reference 38">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Survey%20of%20subjective%20%E2%80%98God%20encounter%20experiences%E2%80%99%3A%20Comparisons%20among%20naturally%20occurring%20experiences%20and%20those%20occasioned%20by%20the%20classic%20psychedelics%20psilocybin%2C%20LSD%2C%20ayahuasca%2C%20or%20DMT&amp;journal=PloS%20ONE.&amp;doi=10.1371%2Fjournal.pone.0214377&amp;volume=14&amp;publication_year=2019&amp;author=Griffiths%2CRR&amp;author=Hurwitz%2CES&amp;author=Davis%2CAK&amp;author=Johnson%2CMW&amp;author=Jesse%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="39."><p id="ref-CR39">Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacol (Berl). 2017;234:1499–510. <a href="https://doi.org/10.1007/s00213-016-4453-0">https://doi.org/10.1007/s00213-016-4453-0</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00213-016-4453-0" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00213-016-4453-0" aria-label="Article reference 39" data-doi="10.1007/s00213-016-4453-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1ehsrnO" aria-label="CAS reference 39">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Alterations%20of%20consciousness%20and%20mystical-type%20experiences%20after%20acute%20LSD%20in%20humans&amp;journal=Psychopharmacol%20%28Berl%29.&amp;doi=10.1007%2Fs00213-016-4453-0&amp;volume=234&amp;pages=1499-510&amp;publication_year=2017&amp;author=Liechti%2CME&amp;author=Dolder%2CPC&amp;author=Schmid%2CY">
                    Google Scholar</a> 
                </p></li><li data-counter="40."><p id="ref-CR40">Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stampfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082 <a href="https://doi.org/10.7554/eLife.35082">https://doi.org/10.7554/eLife.35082</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.7554/eLife.35082" data-track-action="article reference" href="https://doi.org/10.7554%2FeLife.35082" aria-label="Article reference 40" data-doi="10.7554/eLife.35082">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30355445" aria-label="PubMed reference 40">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202055" aria-label="PubMed Central reference 40">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Changes%20in%20global%20and%20thalamic%20brain%20connectivity%20in%20LSD-induced%20altered%20states%20of%20consciousness%20are%20attributable%20to%20the%205-HT2A%20receptor&amp;journal=Elife&amp;doi=10.7554%2FeLife.35082&amp;volume=7&amp;publication_year=2018&amp;author=Preller%2CKH&amp;author=Burt%2CJB&amp;author=Ji%2CJL&amp;author=Schleifer%2CCH&amp;author=Adkinson%2CBD&amp;author=Stampfli%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="41."><p id="ref-CR41">Müller F, Lenz C, Dolder P, Lang U, Schmidt A, Liechti M, et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand. 2017;136:648–57. <a href="https://doi.org/10.1111/acps.12818">https://doi.org/10.1111/acps.12818</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/acps.12818" data-track-action="article reference" href="https://doi.org/10.1111%2Facps.12818" aria-label="Article reference 41" data-doi="10.1111/acps.12818">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslyhsb7E" aria-label="CAS reference 41">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28940312" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698745" aria-label="PubMed Central reference 41">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Increased%20thalamic%20resting-state%20connectivity%20as%20a%20core%20driver%20of%20LSD-induced%20hallucinations&amp;journal=Acta%20Psychiatr%20Scand.&amp;doi=10.1111%2Facps.12818&amp;volume=136&amp;pages=648-57&amp;publication_year=2017&amp;author=M%C3%BCller%2CF&amp;author=Lenz%2CC&amp;author=Dolder%2CP&amp;author=Lang%2CU&amp;author=Schmidt%2CA&amp;author=Liechti%2CM">
                    Google Scholar</a> 
                </p></li><li data-counter="42."><p id="ref-CR42">Holze F, Duthaler U, Vizeli P, Müller F, Borgwardt S, Liechti ME. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharm. 2019;85:1474–83. <a href="https://doi.org/10.1111/bcp.13918">https://doi.org/10.1111/bcp.13918</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/bcp.13918" data-track-action="article reference" href="https://doi.org/10.1111%2Fbcp.13918" aria-label="Article reference 42" data-doi="10.1111/bcp.13918">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1yisbzN" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Pharmacokinetics%20and%20subjective%20effects%20of%20a%20novel%20oral%20LSD%20formulation%20in%20healthy%20subjects&amp;journal=Br%20J%20Clin%20Pharm.&amp;doi=10.1111%2Fbcp.13918&amp;volume=85&amp;pages=1474-83&amp;publication_year=2019&amp;author=Holze%2CF&amp;author=Duthaler%2CU&amp;author=Vizeli%2CP&amp;author=M%C3%BCller%2CF&amp;author=Borgwardt%2CS&amp;author=Liechti%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="43."><p id="ref-CR43">Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacol (Berl). 2021. <a href="https://doi.org/10.1007/s00213-021-05991-9">https://doi.org/10.1007/s00213-021-05991-9</a>.</p></li><li data-counter="44."><p id="ref-CR44">Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019;86:792–800. <a href="https://doi.org/10.1016/j.biopsych.2019.05.019">https://doi.org/10.1016/j.biopsych.2019.05.019</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.biopsych.2019.05.019" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.biopsych.2019.05.019" aria-label="Article reference 44" data-doi="10.1016/j.biopsych.2019.05.019">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsValsrnP" aria-label="CAS reference 44">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31331617" aria-label="PubMed reference 44">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814527" aria-label="PubMed Central reference 44">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=de%20Wit%20H.%20Acute%20Subjective%20and%20Behavioral%20Effects%20of%20Microdoses%20of%20Lysergic%20Acid%20Diethylamide%20in%20Healthy%20Human%20Volunteers&amp;journal=Biol%20Psychiatry.&amp;doi=10.1016%2Fj.biopsych.2019.05.019&amp;volume=86&amp;pages=792-800&amp;publication_year=2019&amp;author=Bershad%2CAK&amp;author=Schepers%2CST&amp;author=Bremmer%2CMP&amp;author=Lee%2CR&amp;author=de%20Wit%2CH">
                    Google Scholar</a> 
                </p></li><li data-counter="45."><p id="ref-CR45">de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022;27:e13143 <a href="https://doi.org/10.1111/adb.13143">https://doi.org/10.1111/adb.13143</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/adb.13143" data-track-action="article reference" href="https://doi.org/10.1111%2Fadb.13143" aria-label="Article reference 45" data-doi="10.1111/adb.13143">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1SksrjJ" aria-label="CAS reference 45">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35106880" aria-label="PubMed reference 45">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731343" aria-label="PubMed Central reference 45">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Repeated%20low%20doses%20of%20LSD%20in%20healthy%20adults%3A%20A%20placebo-controlled%2C%20dose-response%20study&amp;journal=Addict%20Biol.&amp;doi=10.1111%2Fadb.13143&amp;volume=27&amp;publication_year=2022&amp;author=Wit%2CH&amp;author=Molla%2CHM&amp;author=Bershad%2CA&amp;author=Bremmer%2CM&amp;author=Lee%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="46."><p id="ref-CR46">Holze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clin Pharm Ther. 2021;109:658–66. <a href="https://doi.org/10.1002/cpt.2057">https://doi.org/10.1002/cpt.2057</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/cpt.2057" data-track-action="article reference" href="https://doi.org/10.1002%2Fcpt.2057" aria-label="Article reference 46" data-doi="10.1002/cpt.2057">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXltFKntLk%3D" aria-label="CAS reference 46">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Pharmacokinetics%20and%20Pharmacodynamics%20of%20Lysergic%20Acid%20Diethylamide%20Microdoses%20in%20Healthy%20Participants&amp;journal=Clin%20Pharm%20Ther.&amp;doi=10.1002%2Fcpt.2057&amp;volume=109&amp;pages=658-66&amp;publication_year=2021&amp;author=Holze%2CF&amp;author=Liechti%2CME&amp;author=Hutten%2CNRPW&amp;author=Mason%2CNL&amp;author=Dolder%2CPC&amp;author=Theunissen%2CEL">
                    Google Scholar</a> 
                </p></li><li data-counter="47."><p id="ref-CR47">Dittrich A. Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände [Construction of a questionnaire (APZ) for assessing abnormal mental states]. Z Klin Psychol Psychiatr Psychother. 1975;23:12–20.</p><p><a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Zusammenstellung%20eines%20Fragebogens%20%28APZ%29%20zur%20Erfassung%20abnormer%20psychischer%20Zust%C3%A4nde%20%5BConstruction%20of%20a%20questionnaire%20%28APZ%29%20for%20assessing%20abnormal%20mental%20states%5D&amp;journal=Z%20Klin%20Psychol%20Psychiatr%20Psychother.&amp;volume=23&amp;pages=12-20&amp;publication_year=1975&amp;author=Dittrich%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="48."><p id="ref-CR48">Dittrich A. Ätiologie-unabhängige Strukturen veränderter Wachbewußtseinszustände: Ergebnisse empirischer Untersuchungen über Halluzinogene I. und II. Ordnung, sensorische Deprivation, hypnagoge Zustände, hypnotische Verfahren sowie Reizüberflutung. [Etiology-independent structures of altered states of consciousness. Results of empirical studies on hallucinogens of the first and second order, sensory deprivation, hypnagogic states, hypnotic procedures, and sensory overload]. Enke, Stuttgart, Germany; 1985.</p></li><li data-counter="49."><p id="ref-CR49">Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80–4. <a href="https://doi.org/10.1055/s-2007-979351">https://doi.org/10.1055/s-2007-979351</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1055/s-2007-979351" data-track-action="article reference" href="https://doi.org/10.1055%2Fs-2007-979351" aria-label="Article reference 49" data-doi="10.1055/s-2007-979351">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9754838" aria-label="PubMed reference 49">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20standardized%20psychometric%20assessment%20of%20altered%20states%20of%20consciousness%20%28ASCs%29%20in%20humans&amp;journal=Pharmacopsychiatry&amp;doi=10.1055%2Fs-2007-979351&amp;volume=31&amp;pages=80-4&amp;publication_year=1998&amp;author=Dittrich%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="50."><p id="ref-CR50">Bodmer I, Dittrich A, Lamparter D. Aussergewöhnliche Bewusstseinszustände-Ihre gemeinsame Struktur und Messung [Altered states of consciousness-Their common structure and assessment]. Welten Bewusstseins Bd. 1994;3:45–58.</p><p><a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Aussergew%C3%B6hnliche%20Bewusstseinszust%C3%A4nde-Ihre%20gemeinsame%20Struktur%20und%20Messung%20%5BAltered%20states%20of%20consciousness-Their%20common%20structure%20and%20assessment%5D&amp;journal=Welten%20Bewusstseins%20Bd.&amp;volume=3&amp;pages=45-58&amp;publication_year=1994&amp;author=Bodmer%2CI&amp;author=Dittrich%2CA&amp;author=Lamparter%2CD">
                    Google Scholar</a> 
                </p></li><li data-counter="51."><p id="ref-CR51">Dittrich A, Lamparter D, Maurer M. 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]. PSIN PLUS, Zurich, Switzerland; 2006.</p></li><li data-counter="52."><p id="ref-CR52">Studerus E, Gamma A, Vollenweider FX. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE. 2010;5:e12412 <a href="https://doi.org/10.1371/journal.pone.0012412">https://doi.org/10.1371/journal.pone.0012412</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0012412" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0012412" aria-label="Article reference 52" data-doi="10.1371/journal.pone.0012412">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtFWktb%2FE" aria-label="CAS reference 52">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20824211" aria-label="PubMed reference 52">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930851" aria-label="PubMed Central reference 52">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychometric%20Evaluation%20of%20the%20Altered%20States%20of%20Consciousness%20Rating%20Scale%20%28OAV&amp;journal=PLoS%20ONE.&amp;doi=10.1371%2Fjournal.pone.0012412&amp;volume=5&amp;publication_year=2010&amp;author=Studerus%2CE&amp;author=Gamma%2CA&amp;author=Vollenweider%2CFX">
                    Google Scholar</a> 
                </p></li><li data-counter="53."><p id="ref-CR53">Dittrich A, Lamparter D, Maurer M. 5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction. 3rd ed. PSIN PLUS, Zurich, Switzerland; 2010.</p></li><li data-counter="54."><p id="ref-CR54">MacLean KA, Leoutsakos J-MS, Johnson MW, Griffiths RR. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig. 2012;51:721–37. <a href="https://doi.org/10.1111/j.1468-5906.2012.01685.x">https://doi.org/10.1111/j.1468-5906.2012.01685.x</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/j.1468-5906.2012.01685.x" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1468-5906.2012.01685.x" aria-label="Article reference 54" data-doi="10.1111/j.1468-5906.2012.01685.x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23316089" aria-label="PubMed reference 54">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539773" aria-label="PubMed Central reference 54">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Factor%20Analysis%20of%20the%20Mystical%20Experience%20Questionnaire%3A%20A%20Study%20of%20Experiences%20Occasioned%20by%20the%20Hallucinogen%20Psilocybin&amp;journal=J%20Sci%20Study%20Relig.&amp;doi=10.1111%2Fj.1468-5906.2012.01685.x&amp;volume=51&amp;pages=721-37&amp;publication_year=2012&amp;author=MacLean%2CKA&amp;author=Leoutsakos%2CJ-MS&amp;author=Johnson%2CMW&amp;author=Griffiths%2CRR">
                    Google Scholar</a> 
                </p></li><li data-counter="55."><p id="ref-CR55">Barrett FS, Griffiths RR. The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016. Hum Psychopharmacol. 2017;32:1 <a href="https://doi.org/10.1002/hup.2564">https://doi.org/10.1002/hup.2564</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/hup.2564" data-track-action="article reference" href="https://doi.org/10.1002%2Fhup.2564" aria-label="Article reference 55" data-doi="10.1002/hup.2564">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20factor%20structure%20of%20the%20Mystical%20Experience%20Questionnaire%20%28MEQ%29%3A%20Reply%20to%20Bouso%20et%20al.%2C%202016&amp;journal=Hum%20Psychopharmacol.&amp;doi=10.1002%2Fhup.2564&amp;volume=32&amp;publication_year=2017&amp;author=Barrett%2CFS&amp;author=Griffiths%2CRR">
                    Google Scholar</a> 
                </p></li><li data-counter="56."><p id="ref-CR56">Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol (Oxf). 2015;29:1182–90. <a href="https://doi.org/10.1177/0269881115609019">https://doi.org/10.1177/0269881115609019</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881115609019" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881115609019" aria-label="Article reference 56" data-doi="10.1177/0269881115609019">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xns1Crsrw%3D" aria-label="CAS reference 56">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Validation%20of%20the%20revised%20Mystical%20Experience%20Questionnaire%20in%20experimental%20sessions%20with%20psilocybin&amp;journal=J%20Psychopharmacol%20%28Oxf%29.&amp;doi=10.1177%2F0269881115609019&amp;volume=29&amp;pages=1182-90&amp;publication_year=2015&amp;author=Barrett%2CFS&amp;author=Johnson%2CMW&amp;author=Griffiths%2CRR">
                    Google Scholar</a> 
                </p></li><li data-counter="57."><p id="ref-CR57">Stone CJ, Koo C-Y. Additive Splines in Statistics. American Statistical Association, Washington DC. 1985.</p></li><li data-counter="58."><p id="ref-CR58">Harrell FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198–202. <a href="https://doi.org/10.1093/jnci/80.15.1198">https://doi.org/10.1093/jnci/80.15.1198</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/jnci/80.15.1198" data-track-action="article reference" href="https://doi.org/10.1093%2Fjnci%2F80.15.1198" aria-label="Article reference 58" data-doi="10.1093/jnci/80.15.1198">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=3047407" aria-label="PubMed reference 58">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Regression%20models%20in%20clinical%20studies%3A%20determining%20relationships%20between%20predictors%20and%20response&amp;journal=J%20Natl%20Cancer%20Inst.&amp;doi=10.1093%2Fjnci%2F80.15.1198&amp;volume=80&amp;pages=1198-202&amp;publication_year=1988&amp;author=Harrell%2CFE&amp;author=Lee%2CKL&amp;author=Pollock%2CBG">
                    Google Scholar</a> 
                </p></li><li data-counter="59."><p id="ref-CR59">Harrell FE. Multivariable Modeling Strategies. In: Harrell Jr Frank E, editor. Regres. Model. Strateg. Appl. Linear Models Logist. Ordinal Regres. Surviv. Anal., Cham: Springer International Publishing; 2015. p. 63–102. <a href="https://doi.org/10.1007/978-3-319-19425-7_4">https://doi.org/10.1007/978-3-319-19425-7_4</a>.</p></li><li data-counter="60."><p id="ref-CR60">Pustejovsky JE, Tipton E. Small-Sample Methods for Cluster-Robust Variance Estimation and Hypothesis Testing in Fixed Effects Models. J Bus Econ Stat. 2018;36:672–83. <a href="https://doi.org/10.1080/07350015.2016.1247004">https://doi.org/10.1080/07350015.2016.1247004</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/07350015.2016.1247004" data-track-action="article reference" href="https://doi.org/10.1080%2F07350015.2016.1247004" aria-label="Article reference 60" data-doi="10.1080/07350015.2016.1247004">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=Small-Sample%20Methods%20for%20Cluster-Robust%20Variance%20Estimation%20and%20Hypothesis%20Testing%20in%20Fixed%20Effects%20Models&amp;journal=J%20Bus%20Econ%20Stat.&amp;doi=10.1080%2F07350015.2016.1247004&amp;volume=36&amp;pages=672-83&amp;publication_year=2018&amp;author=Pustejovsky%2CJE&amp;author=Tipton%2CE">
                    Google Scholar</a> 
                </p></li><li data-counter="61."><p id="ref-CR61">R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <a href="https://www.R-project.org/">https://www.R-project.org/</a>. 2022.</p></li><li data-counter="62."><p id="ref-CR62">Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48. <a href="https://doi.org/10.18637/jss.v036.i03">https://doi.org/10.18637/jss.v036.i03</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.18637/jss.v036.i03" data-track-action="article reference" href="https://doi.org/10.18637%2Fjss.v036.i03" aria-label="Article reference 62" data-doi="10.18637/jss.v036.i03">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Conducting%20meta-analyses%20in%20R%20with%20the%20metafor%20package&amp;journal=J%20Stat%20Softw.&amp;doi=10.18637%2Fjss.v036.i03&amp;volume=36&amp;issue=3&amp;pages=1-48&amp;publication_year=2010&amp;author=Viechtbauer%2CW">
                    Google Scholar</a> 
                </p></li><li data-counter="63."><p id="ref-CR63">Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PLOS ONE. 2015;10:e0146021 <a href="https://doi.org/10.1371/journal.pone.0146021">https://doi.org/10.1371/journal.pone.0146021</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0146021" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0146021" aria-label="Article reference 63" data-doi="10.1371/journal.pone.0146021">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XisVSmt7c%3D" aria-label="CAS reference 63">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26717316" aria-label="PubMed reference 63">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696819" aria-label="PubMed Central reference 63">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Dose-Response%20Analysis%20Using%20R&amp;journal=PLOS%20ONE.&amp;doi=10.1371%2Fjournal.pone.0146021&amp;volume=10&amp;publication_year=2015&amp;author=Ritz%2CC&amp;author=Baty%2CF&amp;author=Streibig%2CJC&amp;author=Gerhard%2CD">
                    Google Scholar</a> 
                </p></li><li data-counter="64."><p id="ref-CR64">Pustejovsky J. clubSandwich: Cluster-Robust (Sandwich) Variance Estimators with Small-Sample Corrections. R package version 0.5.8.9999. <a href="http://jepusto.github.io/clubSandwich/">http://jepusto.github.io/clubSandwich/</a>. 2023.</p></li><li data-counter="65."><p id="ref-CR65">Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol. Cham: Springer International Publishing; 2022. p. 3–21. <a href="https://doi.org/10.1007/7854_2021_270">https://doi.org/10.1007/7854_2021_270</a>.</p></li><li data-counter="66."><p id="ref-CR66">Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379–90. <a href="https://doi.org/10.1017/S0033291715002901">https://doi.org/10.1017/S0033291715002901</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1017/S0033291715002901" data-track-action="article reference" href="https://doi.org/10.1017%2FS0033291715002901" aria-label="Article reference 66" data-doi="10.1017/S0033291715002901">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC28nnvVaksw%3D%3D" aria-label="CAS reference 66">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26847689" aria-label="PubMed reference 66">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20paradoxical%20psychological%20effects%20of%20lysergic%20acid%20diethylamide%20%28LSD%29&amp;journal=Psychol%20Med.&amp;doi=10.1017%2FS0033291715002901&amp;volume=46&amp;pages=1379-90&amp;publication_year=2016&amp;author=Carhart-Harris%2CRL&amp;author=Kaelen%2CM&amp;author=Bolstridge%2CM&amp;author=Williams%2CTM&amp;author=Williams%2CLT&amp;author=Underwood%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="67."><p id="ref-CR67">Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2020;45:462–71. <a href="https://doi.org/10.1038/s41386-019-0569-3">https://doi.org/10.1038/s41386-019-0569-3</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41386-019-0569-3" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41386-019-0569-3" aria-label="Article reference 67" data-doi="10.1038/s41386-019-0569-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFyrtbvI" aria-label="CAS reference 67">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Distinct%20acute%20effects%20of%20LSD%2C%20MDMA%2C%20and%20D-amphetamine%20in%20healthy%20subjects&amp;journal=Neuropsychopharmacol%20Publ%20Am%20Coll%20Neuropsychopharmacol.&amp;doi=10.1038%2Fs41386-019-0569-3&amp;volume=45&amp;pages=462-71&amp;publication_year=2020&amp;author=Holze%2CF&amp;author=Vizeli%2CP&amp;author=M%C3%BCller%2CF&amp;author=Ley%2CL&amp;author=Duerig%2CR&amp;author=Varghese%2CN">
                    Google Scholar</a> 
                </p></li><li data-counter="68."><p id="ref-CR68">Wießner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, Tófoli LF. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2021;53:1–15. <a href="https://doi.org/10.1017/S0033291721002531">https://doi.org/10.1017/S0033291721002531</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1017/S0033291721002531" data-track-action="article reference" href="https://doi.org/10.1017%2FS0033291721002531" aria-label="Article reference 68" data-doi="10.1017/S0033291721002531">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=LSD%2C%20madness%20and%20healing%3A%20Mystical%20experiences%20as%20possible%20link%20between%20psychosis%20model%20and%20therapy%20model&amp;journal=Psychol%20Med.&amp;doi=10.1017%2FS0033291721002531&amp;volume=53&amp;pages=1-15&amp;publication_year=2021&amp;author=Wie%C3%9Fner%2CI&amp;author=Falchi%2CM&amp;author=Palhano-Fontes%2CF&amp;author=Feilding%2CA&amp;author=Ribeiro%2CS&amp;author=T%C3%B3foli%2CLF">
                    Google Scholar</a> 
                </p></li><li data-counter="69."><p id="ref-CR69">Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93:215–23. <a href="https://doi.org/10.1016/j.biopsych.2022.08.025">https://doi.org/10.1016/j.biopsych.2022.08.025</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.biopsych.2022.08.025" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.biopsych.2022.08.025" aria-label="Article reference 69" data-doi="10.1016/j.biopsych.2022.08.025">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XislShtLzE" aria-label="CAS reference 69">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36266118" aria-label="PubMed reference 69">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Lysergic%20Acid%20Diethylamide%E2%80%93Assisted%20Therapy%20in%20Patients%20With%20Anxiety%20With%20and%20Without%20a%20Life-Threatening%20Illness%3A%20A%20Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Phase%20II%20Study&amp;journal=Biol%20Psychiatry.&amp;doi=10.1016%2Fj.biopsych.2022.08.025&amp;volume=93&amp;pages=215-23&amp;publication_year=2023&amp;author=Holze%2CF&amp;author=Gasser%2CP&amp;author=M%C3%BCller%2CF&amp;author=Dolder%2CPC&amp;author=Liechti%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="70."><p id="ref-CR70">Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry. 2022;13:917199. <a href="https://doi.org/10.3389/fpsyt.2022.917199">https://doi.org/10.3389/fpsyt.2022.917199</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fpsyt.2022.917199" data-track-action="article reference" href="https://doi.org/10.3389%2Ffpsyt.2022.917199" aria-label="Article reference 70" data-doi="10.3389/fpsyt.2022.917199">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35923458" aria-label="PubMed reference 70">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340494" aria-label="PubMed Central reference 70">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychedelics%2C%20Mystical%20Experience%2C%20and%20Therapeutic%20Efficacy%3A%20A%20Systematic%20Review&amp;journal=Front%20Psychiatry.&amp;doi=10.3389%2Ffpsyt.2022.917199&amp;volume=13&amp;publication_year=2022&amp;author=Ko%2CK&amp;author=Knight%2CG&amp;author=Rucker%2CJJ&amp;author=Cleare%2CAJ">
                    Google Scholar</a> 
                </p></li><li data-counter="71."><p id="ref-CR71">Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, et al. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol (Oxf). 2022;36:321–36. <a href="https://doi.org/10.1177/02698811211069103">https://doi.org/10.1177/02698811211069103</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/02698811211069103" data-track-action="article reference" href="https://doi.org/10.1177%2F02698811211069103" aria-label="Article reference 71" data-doi="10.1177/02698811211069103">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XmtVKms7c%3D" aria-label="CAS reference 71">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 71" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20tolerability%2C%20pharmacokinetics%2C%20and%20subjective%20effects%20of%2050%2C%2075%2C%20and%20100%20%C2%B5g%20LSD%20in%20healthy%20participants%20within%20a%20novel%20intervention%20paradigm%3A%20A%20proof-of-concept%20study&amp;journal=J%20Psychopharmacol%20%28Oxf%29.&amp;doi=10.1177%2F02698811211069103&amp;volume=36&amp;pages=321-36&amp;publication_year=2022&amp;author=Family%2CN&amp;author=Hendricks%2CPS&amp;author=Williams%2CLT&amp;author=Luke%2CD&amp;author=Krediet%2CE&amp;author=Maillet%2CEL">
                    Google Scholar</a> 
                </p></li><li data-counter="72."><p id="ref-CR72">Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law. 2017;3:2050324516683325. <a href="https://doi.org/10.1177/2050324516683325">https://doi.org/10.1177/2050324516683325</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/2050324516683325" data-track-action="article reference" href="https://doi.org/10.1177%2F2050324516683325" aria-label="Article reference 72" data-doi="10.1177/2050324516683325">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=Constructing%20drug%20effects%3A%20A%20history%20of%20set%20and%20setting&amp;journal=Drug%20Sci%20Policy%20Law.&amp;doi=10.1177%2F2050324516683325&amp;volume=3&amp;publication_year=2017&amp;author=Hartogsohn%2CI">
                    Google Scholar</a> 
                </p></li><li data-counter="73."><p id="ref-CR73">Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS. States and traits related to the quality and consequences of psychedelic experiences. Psychol Conscious Theory Res Pr. 2019;6:1–21. <a href="https://doi.org/10.1037/cns0000169">https://doi.org/10.1037/cns0000169</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1037/cns0000169" data-track-action="article reference" href="https://doi.org/10.1037%2Fcns0000169" aria-label="Article reference 73" data-doi="10.1037/cns0000169">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 73" href="http://scholar.google.com/scholar_lookup?&amp;title=States%20and%20traits%20related%20to%20the%20quality%20and%20consequences%20of%20psychedelic%20experiences&amp;journal=Psychol%20Conscious%20Theory%20Res%20Pr.&amp;doi=10.1037%2Fcns0000169&amp;volume=6&amp;pages=1-21&amp;publication_year=2019&amp;author=Russ%2CSL&amp;author=Carhart-Harris%2CRL&amp;author=Maruyama%2CG&amp;author=Elliott%2CMS">
                    Google Scholar</a> 
                </p></li><li data-counter="74."><p id="ref-CR74">Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting Responses to Psychedelics: A Prospective Study. Front Pharm. 2018;9:897. <a href="https://doi.org/10.3389/fphar.2018.00897">https://doi.org/10.3389/fphar.2018.00897</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fphar.2018.00897" data-track-action="article reference" href="https://doi.org/10.3389%2Ffphar.2018.00897" aria-label="Article reference 74" data-doi="10.3389/fphar.2018.00897">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGmurzJ" aria-label="CAS reference 74">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 74" href="http://scholar.google.com/scholar_lookup?&amp;title=Predicting%20Responses%20to%20Psychedelics%3A%20A%20Prospective%20Study&amp;journal=Front%20Pharm.&amp;doi=10.3389%2Ffphar.2018.00897&amp;volume=9&amp;publication_year=2018&amp;author=Haijen%2CECHM&amp;author=Kaelen%2CM&amp;author=Roseman%2CL&amp;author=Timmermann%2CC&amp;author=Kettner%2CH&amp;author=Russ%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="75."><p id="ref-CR75">Savage C. The resolution and subsequent remobilization of resistance by LSD in psychotherapy. J Nerv Ment Dis. 1957;125:434–7. <a href="https://doi.org/10.1097/00005053-195707000-00015">https://doi.org/10.1097/00005053-195707000-00015</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/00005053-195707000-00015" data-track-action="article reference" href="https://doi.org/10.1097%2F00005053-195707000-00015" aria-label="Article reference 75" data-doi="10.1097/00005053-195707000-00015">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaG1c%2FisVCntw%3D%3D" aria-label="CAS reference 75">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=13481750" aria-label="PubMed reference 75">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 75" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20resolution%20and%20subsequent%20remobilization%20of%20resistance%20by%20LSD%20in%20psychotherapy&amp;journal=J%20Nerv%20Ment%20Dis.&amp;doi=10.1097%2F00005053-195707000-00015&amp;volume=125&amp;pages=434-7&amp;publication_year=1957&amp;author=Savage%2CC">
                    Google Scholar</a> 
                </p></li><li data-counter="76."><p id="ref-CR76">Lewis CR, Preller KH, Braden BB, Riecken C, Vollenweider FX. Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. Biomedicines. 2020;8:34. <a href="https://doi.org/10.3390/biomedicines8020034">https://doi.org/10.3390/biomedicines8020034</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3390/biomedicines8020034" data-track-action="article reference" href="https://doi.org/10.3390%2Fbiomedicines8020034" aria-label="Article reference 76" data-doi="10.3390/biomedicines8020034">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlant7vI" aria-label="CAS reference 76">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32085521" aria-label="PubMed reference 76">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168190" aria-label="PubMed Central reference 76">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 76" href="http://scholar.google.com/scholar_lookup?&amp;title=Rostral%20Anterior%20Cingulate%20Thickness%20Predicts%20the%20Emotional%20Psilocybin%20Experience&amp;journal=Biomedicines&amp;doi=10.3390%2Fbiomedicines8020034&amp;volume=8&amp;publication_year=2020&amp;author=Lewis%2CCR&amp;author=Preller%2CKH&amp;author=Braden%2CBB&amp;author=Riecken%2CC&amp;author=Vollenweider%2CFX">
                    Google Scholar</a> 
                </p></li><li data-counter="77."><p id="ref-CR77">Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep. 2021;11:10851. <a href="https://doi.org/10.1038/s41598-021-90343-y">https://doi.org/10.1038/s41598-021-90343-y</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41598-021-90343-y" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41598-021-90343-y" aria-label="Article reference 77" data-doi="10.1038/s41598-021-90343-y">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtF2ntL3K" aria-label="CAS reference 77">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34035391" aria-label="PubMed reference 77">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149637" aria-label="PubMed Central reference 77">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 77" href="http://scholar.google.com/scholar_lookup?&amp;title=Genetic%20influence%20of%20CYP2D6%20on%20pharmacokinetics%20and%20acute%20subjective%20effects%20of%20LSD%20in%20a%20pooled%20analysis&amp;journal=Sci%20Rep.&amp;doi=10.1038%2Fs41598-021-90343-y&amp;volume=11&amp;publication_year=2021&amp;author=Vizeli%2CP&amp;author=Straumann%2CI&amp;author=Holze%2CF&amp;author=Schmid%2CY&amp;author=Dolder%2CPC&amp;author=Liechti%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="78."><p id="ref-CR78">Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. 2016;113:4853–8. <a href="https://doi.org/10.1073/pnas.1518377113">https://doi.org/10.1073/pnas.1518377113</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1073/pnas.1518377113" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1518377113" aria-label="Article reference 78" data-doi="10.1073/pnas.1518377113">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xlsl2nsbs%3D" aria-label="CAS reference 78">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27071089" aria-label="PubMed reference 78">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855588" aria-label="PubMed Central reference 78">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 78" href="http://scholar.google.com/scholar_lookup?&amp;title=Neural%20correlates%20of%20the%20LSD%20experience%20revealed%20by%20multimodal%20neuroimaging&amp;journal=Proc%20Natl%20Acad%20Sci%20USA.&amp;doi=10.1073%2Fpnas.1518377113&amp;volume=113&amp;pages=4853-8&amp;publication_year=2016&amp;author=Carhart-Harris%2CRL&amp;author=Muthukumaraswamy%2CS&amp;author=Roseman%2CL&amp;author=Kaelen%2CM&amp;author=Droog%2CW&amp;author=Murphy%2CK">
                    Google Scholar</a> 
                </p></li><li data-counter="79."><p id="ref-CR79">Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacol Berl. 2020;237:841–53. <a href="https://doi.org/10.1007/s00213-019-05417-7">https://doi.org/10.1007/s00213-019-05417-7</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00213-019-05417-7" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00213-019-05417-7" aria-label="Article reference 79" data-doi="10.1007/s00213-019-05417-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXisVaqs7rK" aria-label="CAS reference 79">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 79" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20tolerability%2C%20pharmacokinetics%2C%20and%20pharmacodynamics%20of%20low%20dose%20lysergic%20acid%20diethylamide%20%28LSD%29%20in%20healthy%20older%20volunteers&amp;journal=Psychopharmacol%20Berl.&amp;doi=10.1007%2Fs00213-019-05417-7&amp;volume=237&amp;pages=841-53&amp;publication_year=2020&amp;author=Family%2CN&amp;author=Maillet%2CEL&amp;author=Williams%2CLTJ&amp;author=Krediet%2CE&amp;author=Carhart-Harris%2CRL&amp;author=Williams%2CTM">
                    Google Scholar</a> 
                </p></li><li data-counter="80."><p id="ref-CR80">Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. Int J Neuropsychopharmacol. 2023;26:97–106. <a href="https://doi.org/10.1093/ijnp/pyac075">https://doi.org/10.1093/ijnp/pyac075</a>.</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/ijnp/pyac075" data-track-action="article reference" href="https://doi.org/10.1093%2Fijnp%2Fpyac075" aria-label="Article reference 80" data-doi="10.1093/ijnp/pyac075">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXksFOitr4%3D" aria-label="CAS reference 80">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36342343" aria-label="PubMed reference 80">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 80" href="http://scholar.google.com/scholar_lookup?&amp;title=Ketanserin%20Reverses%20the%20Acute%20Response%20to%20LSD%20in%20a%20Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%2C%20Crossover%20Study%20in%20Healthy%20Participants&amp;journal=Int%20J%20Neuropsychopharmacol.&amp;doi=10.1093%2Fijnp%2Fpyac075&amp;volume=26&amp;pages=97-106&amp;publication_year=2023&amp;author=Becker%2CAM&amp;author=Klaiber%2CA&amp;author=Holze%2CF&amp;author=Istampoulouoglou%2CI&amp;author=Duthaler%2CU&amp;author=Varghese%2CN">
                    Google Scholar</a> 
                </p></li></ol><p><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41386-023-01588-2?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#global-icon-download"></use></svg></a></p></div></div></div></section></div><section data-title="Funding"><div id="Fun-section"><h2 id="Fun">Funding</h2><p>Open Access funding enabled and organized by Projekt DEAL.</p></div></section><section aria-labelledby="author-information" data-title="Author information"><div id="author-information-section"><h2 id="author-information">Author information</h2><div id="author-information-content"><p><span id="author-notes">Author notes</span></p><ol><li id="na1"><p>These authors contributed equally: Tim Hirschfeld, Johanna Prugger.</p></li></ol><h3 id="affiliations">Authors and Affiliations</h3><ol><li id="Aff1"><p>Psychedelic Substances Research Group, Department of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany</p><p>Tim Hirschfeld, Johanna Prugger, Tomislav Majić &amp; Timo T. Schmidt</p></li><li id="Aff2"><p>International Graduate Program Medical Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany</p><p>Johanna Prugger</p></li><li id="Aff3"><p>Department of Psychiatry und Neurosciences, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany</p><p>Tomislav Majić</p></li><li id="Aff4"><p>Department of Education and Psychology, Freie Universität Berlin, 14195, Berlin, Germany</p><p>Timo T. Schmidt</p></li></ol><h3 id="contributions">Contributions</h3><p>TTS initiated and conceptualized the work. JP conducted the literature search and data collection. TH performed the analyses with contributions of TTS. TH, JP, TM, and TTS jointly wrote, edited, and approved the final version of the paper.</p><h3 id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:timo.t.schmidt@fu-berlin.de">Timo T. Schmidt</a>.</p></div></div></section><section data-title="Ethics declarations"><div id="ethics-section"><h2 id="ethics">Ethics declarations</h2><div id="ethics-content">
            
              <h3 id="FPar1">Competing interests</h3>
              <p>The authors declare no competing interests.</p>
            
          </div></div></section><section data-title="Additional information"><div id="additional-information-section"><h2 id="additional-information">Additional information</h2><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></section><section data-title="Supplementary information"><div id="Sec10-section"><h2 id="Sec10">Supplementary information</h2></div></section><section data-title="Rights and permissions"><div id="rightslink-section"><h2 id="rightslink">Rights and permissions</h2><div id="rightslink-content">
              <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
            <p><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Dose-response%20relationships%20of%20LSD-induced%20subjective%20experiences%20in%20humans&amp;author=Tim%20Hirschfeld%20et%20al&amp;contentID=10.1038%2Fs41386-023-01588-2&amp;copyright=The%20Author%28s%29&amp;publication=0893-133X&amp;publicationDate=2023-05-09&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and Permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div id="article-info-section"><h2 id="article-info">About this article</h2><div id="article-info-content"><div><p><a data-crossmark="10.1038/s41386-023-01588-2" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41386-023-01588-2" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img width="57" height="81" alt="Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"/></a></p><div><h3 id="citeas">Cite this article</h3><p>Hirschfeld, T., Prugger, J., Majić, T. <i>et al.</i> Dose-response relationships of LSD-induced subjective experiences in humans.
                    <i>Neuropsychopharmacol.</i>  (2023). https://doi.org/10.1038/s41386-023-01588-2</p><p><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41386-023-01588-2?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#global-icon-download"></use></svg></a></p><ul data-test="publication-history"><li><p>Received<span>: </span><span><time datetime="2022-10-25">25 October 2022</time></span></p></li><li><p>Revised<span>: </span><span><time datetime="2023-03-19">19 March 2023</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime="2023-04-12">12 April 2023</time></span></p></li><li><p>Published<span>: </span><span><time datetime="2023-05-09">09 May 2023</time></span></p></li><li><p><abbr title="Digital Object Identifier">DOI</abbr><span>: </span><span>https://doi.org/10.1038/s41386-023-01588-2</span></p></li></ul></div></div></div></div></section>
            </div>

            

            
</div>
</article></div>
  </body>
</html>
